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Abstract
Gangliosides have been implicated in multiple pathologies affecting the central
nervous system (CNS) and recent research has implicated them in playing an active role in the
pathogenesis of multiple sclerosis.

Empirical studies and theoretical considerations have

suggested the possibility of interactions between gangliosides, like GD3, and pro-inflammatory
cytokines present in the nervous system. This study sought to investigate the possibility that
either individual gangliosides acting alone or complexed with other species interact with the
known immune response factor TNFα to initiate or facilitate cell death in the CNS.

We

examined the cellular viability and gene expression in primary brain cell cultures treated with
either GD3, GD1b, or TNF to observe relative changes that would provide evidence for a
possible pathway involved in this form of cell death. We found that both GD3 and GD1b, but
not TNF led to up-regulation of gene expression for macrophage inflammatory protein 3
(MIP3A) and interleukin-1 receptor 1 (IL1R1), but down-regulation of fibroblast growth factor
13 (FGF13). The gene expression of the FGF receptor activating protein 1 (FRAG1) and
interleukin-3 receptor alpha (IL3RA) was down-regulated by GD3 and GD1b for IL3RA, but
only GD3 caused a down-regulation in FRAG1, while TNFcausedanup-regulated in the
expression of both genes.

All three treatments resulted in up-regulation of the gene for

chemokine ligand 2 (CCL2). TNF was also found to increase expression of the gene for Nacetyl-galactosaminyl transferase (GNT), a key enzyme in the synthesis of more complex
gangliosides. These findings support the view that a pro-inflammatory stimulus, like TNF,
activates biosynthesis of gangliosides, which subsequently breaks down to forms not normally
expressed in differentiated cells, like GD3, which then lead to or modulate cell death.
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Chapter I
INTRODUCTION
Gangliosides are membrane-bound glycolipids that are found in abundance in neuronal
membranes. They occur predominantly in the central nervous system (CNS) and are commonly
found sequestered in lipid raft domains of the membrane. Gangliosides have been associated
with cell-cell communication, cell-macromolecule communication, and are targets for multiple
pathogens such as Clostridium botulinum, Clostridium tetani, Vibrio cholerae, and influenza. In
addition, they have multiple implications in several diseases including multiple sclerosis (MS)
and Guillain-Barre syndrome, as evidenced by high amounts of anti-ganglioside antibodies
associated with those conditions. They are most notably associated with diseases such as TaySachs and Sandoff’s disease, which are both caused by an accumulation of gangliosides within
the neuron.
More recently gangliosides have also been thought to play a critical role in the pathology
of MS and other autoimmune diseases. Anti-ganglioside antibodies have been produced in vivo
and in vitro and are thought to recognize the carbohydrate portion of the glycolipid (Freimer,
McIntosh et al. 1993; Zaprianova, Majtenyi et al. 2004; Marconi, Acler et al. 2006). This
response may lead to the characteristic breakdown of the blood-brain barrier in MS, causing
infiltration of T-cells into the brain.
The goal of this research was to investigate alternative mechanisms in the pathology of
MS-induced neural cell death. I hypothesized that gangliosides, specifically GD3, play a role in
specific cell death pathways that are implicated in the progression of neuronal death in the course
of MS.
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The completion of these experiments: 1) provided critical information on the putative
role of gangliosides in neuronal apoptosis and MS pathogenesis, 2) generated potentially new
candidate targets of MS pathogenesis, 3) and added to our overall knowledge base of what the
normal function of gangliosides are in the CNS.
Neurodegeneration associated with autoimmunity is a well known dysfunction of the
immune system, misrecognizing and targeting the "self" antigens rather than foreign
pathogens/antigens. Multiple sclerosis is an autoimmune disease that involves T-cells of the
immune system which recognize a component of the myelin sheath of neurons and cause
massive cell death and ultimate dysfunction of the CNS. The myelin sheath acts as an electrical
insulator which allows the propagation of bioelectrical signaling known as action potentials from
neuron to neuron in the CNS and PNS. Loss of proper neuronal communication can lead to
severe motor dysfunction, cognitive disabilities, and eventually death.
The etiology of MS is unknown; however genetic and environmental factors appear to
play a role in the disease. Most patients with MS are Caucasians of European descent and the
frequency of cases diagnosed increases as latitude increases north and south of the equator. One
current hypothesis is that the Epstein-Bar virus may be a possible etiological agent, but there is
not yet sufficient definitive evidence to support this claim (Ascherio and Munger 2007).
Approximately 2.5 million people suffer from this progressive neurodegenerative
disease worldwide, and are treated with medications that target the immune system. These
therapies act on the disease by inhibiting secretion of cytokines like interferon beta and tumor
necrosis factor alpha (TNF) by T-cells, thereby reducing the signal for cells to undergo
inflammation and ultimately apoptosis.

Myelin basic protein (MBP), myelin associated

glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG) are the most highly
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investigated targets for the immune system against the nervous system in MS. However, the
mechanisms of pathogenesis in this cruel disease remain vague and poorly understood.
Most of the available treatments for MS are immunosuppressant drugs that slow the
progression of the disease but do not aid in the repair of the neuronal lesions caused by the
immune response. Overall, however, the cellular and targeting mechanisms for MS are not well
understood and proven effective alternative treatments are still lacking.
Current Research on MS
Immunological Research
Due to the lack of knowledge in MS disease progression and treatment, MS has been
under intense investigation in the past few years to enhance our understanding of the biological
processes that are present in its onset and progression. Novel experiments are underway to
elucidate the potential targets that are involved in the progression of the disease by targeting the
immune system and its dysfunction throughout the course of MS. One such target is the B-cell.
The B-cell is important in the adaptive immune system because of its natural ability to make
antibodies, activate T-cells, and its role in the formation of ectopic germinal centers in the
intermeningeal spaces. For that reason research is being conducted on ways to use monoclonal
antibodies to deplete B-cell populations by targeting CD20 with rituximab (Dalakas 2008). The
rationale behind this treatment is to reduce the expression of two B-cell trophic factors, B-cellactivating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are known to be
up-regulated in the CNS and PNS, along with their receptors, in autoimmune disorders (Dalakas
2008).
Other areas of research are investigating T-cells and their ability to recruit or combine
with other immune factors. Much of the research on MS concentrates on the T-cell because of
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its ability to migrate throughout the endothelial system and lymphatic system. T-cells have the
ability to migrate to sites of potential infection and traverse the endothelium in order to activate
antigen presenting cells (APCs) like macrophages or dendritic cells to kill ingested cargo. T-cells
can migrate back to lymph nodes to cross-talk with B-cells causing T-cell clonal expansion
against the specific antigen peptide sequences, while simultaneously activating B-cells to secrete
antibodies against the same peptide sequences. In human trials using MS patients’ cerebral
spinal fluid (CSF), Shi (2009) has seen an up-regulation of CD4(+)TNF(+)IL-2(-)T-cells. This
phenomenon occurs only during the relapse phase and not during the remission phase of
relapsing-remitting multiple sclerosis (RRMS) suggesting an integrated, concerted, intrathecal
immunological response in MS with an unknown initiating event or cause.
Not all of the research on MS is used to treat or cure the disease. Some of the research is
based on the ability to predict the genetic susceptibility to MS or predict when a relapse may
occur. Satoh (2008) has shown, using six human patients with MS, that during the acute relapse
phase, when compared to the fully remitted phase, the CD3 T-cells have an aberrant regulation
on the transcription factor NF.

This shows that activated T-cells are having problems

controlling the expression of a transcription factor essential in inflammatory responses and
proliferation.
The future of MS treatment and research is said to be patient-specific because of the
single nucleotide polymorphisms (SNPs) found throughout the human genome. These one basepair mutations can cause the loss or aberration of the function of a gene leading to the onset of a
disease. Hoppenbrouwers (2008), mentions the genes that are well established to play a role in
the susceptibility and progression of MS, which are human leukocyte antigen DRB1 (HLADRB1), interleukin receptor 2A (IL2RA) and interleukin receptor 7A (IL7RA), all of which are
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involved in proper antigen presentation and immune function; but they also mention that other
novel genes are being discovered as well. They found that ecotropic viral integration site 5
(EVI5) may also play a significant role in MS. Although the function of this gene is still
relatively unknown and is thought to play a role in centrosome stability and dynamics, many
more genes in the genome may play a role in MS in conjunction with or independent of other
known targets as well.
Role of TNF in Autoimmunity
TNF is a known cytokine that is very influential in the initiation of inflammation,
apoptosis and, in some cases, cell survival. Researchers have been trying to link TNFmediated
pathways with autoimmune diseases like MS. One of the potential findings is that TNF
interacts with the ganglioside GD3 causing release of reactive oxygen species (ROS) and
cytochrome c, caspase 3 activation, and NF suppression resulting in apoptosis of various cell
types (Garcia-Ruiz, Colell et al. 2000; Colell, Garcia-Ruiz et al. 2001; Garcia-Ruiz, Colell et al.
2002). Kauffman (2007) tried to link a known SNP at position 376 on the TNF gene known to
increase the susceptibility of MS in patients from Spain (Fernandez-Arquero, Arroyo et al.
1999), but no correlation could be found in patients from the U.S. or the Netherlands, compared
to patients from Argentina.
On the other hand, Favorova (2006) found a very distinct correlation between 238TNFB1 and -308TNFA2, with tri-allelic combinations, and a bi-allelic combination with
TNF9 in Russian patients with MS. This shows the complexity of genetic variation with
different SNPs in alleles along with other allelic interactions or mutations and how treating the
patient is key rather than a global treatment for MS. The next logical step would be to block
TNF signaling to prevent apoptosis during relapses. But anti-TNF drugs have been given to
5

people with rheumatoid arthritis (RA) with very limited success. Mohan (2001) has reported that
patients who have received the anti-TNF drugs experienced confusion and difficulty walking,
suggesting that patients with MS would not be good candidates for this type of treatment since
RA patients mimic the symptoms of MS with this treatment. However, a recent finding (Kim
and Moudgil 2008) has shown that TNF and interferon-gamma (IFN) can reduce arthritic
inflammation and even contribute to the resistance of arthritis. This shows that there is a fine
balance when it comes to TNF and its functionality in of against the cell.
Roles of Other Cytokines in MS
Many other cytokines and chemokines play a role in MS autoimmunity which leads to
neurodegeneration. The most commonly known cytokine that has been implicated in MS is
interleukin 12 (IL-12). Segal (1998) demonstrated that there is an IL-12/IL-10 axis involved in
animals with the neurodegenerative model experimental autoimmune encephalomyelitis (EAE).
They showed that IL-12 secretion is an essential cytokine for the production of Th1 auto-reactive
cells. They also showed that IL-10 is a negative regulator of IL-12 production and that both
cytokines are necessary for the initiation and termination of an immune response by Th1 cells.
Some of the current treatments for MS use interferon-beta (IFN as an immunosuppressant.
IFN acts as an anti-inflammatory and can increase the integrity of the blood-brain barrier.
Byrnes (2002) showed that patients taking IFN

-12/IL-10 axis meaning

that the blood samples from the patients contained more IL-10 than IL-12. This has shown to be
beneficial because IL-10 is negatively affecting Th1 autoimmune cells.
Another potential cytokine that may play a role in MS is IL-6. The normal functions for
IL-6 is to initiate immune responses to trauma, induce fever, indirectly activate Toll-like
receptors ((TLRs), receptors of the innate immune system that recognize structures of microbes
6

and activate an immune response)) , and respond to inflammation. (Serada, Fujimoto et al. 2008)
showed that EAE animals treated with an IL-6r monoclonal antibody blocked the signal
transduction of IL-6 and a consequent reduction of CD4+, CD8+, and Th17 lymph nodal T-cells
specific for myelin oligodendrocyte glycoprotein (MOG) peptides.
Neurological Research on Neurodegeneration
Much research is being done by neuroscientists to better understand the underlying
mechanisms in neurodegeneration. Some of the hot topics in the field of neurodegeneration deal
with diseases like MS or Alzheimer’s disease and the possibility of nerve regrowth and
remyelination of damaged neurons. Others focus on the molecular mechanisms and pathways
involving the cellular communication and apoptosis of neurons. Okun (2009) has suggested that
toll-like receptors (TLRs) may play a role in the targeting and apoptosis of neurons. They found
that glial cells (astrocytes, oligodendrocytes, and microglia) and lymphocytes that invade the
CNS contain activated TLRs that may indirectly cause cell death or damage. This is achieved by
the ability of TLRs to stimulate the immune cells, including microglia, to secrete proinflammatory cytokines and up-regulate cell adhesion molecules in response to inflammation.
Kaminska (2005) has suggested that the main role of p38 MAPK in activation is to
produce and activate multiple inflammatory mediators. Others believe that lipids and their
functions in the brain may play an important role in many diseases. Adibhatla (2008) have
compiled a review implicating lipids, enzymes that control lipid metabolism, and lipoprotein
transporters of lipids for numerous brain disorders like Parkinson’s, Alzheimer’s, Niemann-Pick
disease, amyotrophic lateral sclerosis, and multiple sclerosis. They stated that the inhibition of
the phospholipase A2 (PLA2) in EAE animals lessened the onset and progression of the model
for MS. This makes sense because PLA2 increases cellular amounts of arachidonic acid which is
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the precursor to several inflammatory intermediates like eicosanoids (prostaglandins and
leukotrienes). Lipids probably play a major role in neurodegeneration due to the fact that the
brain contains vast amounts of lipids.

The most important area of research in this field, in my

opinion, is in novel treatments and drug development. One recently published study strongly
suggests that the neurohormone prolactin may be a potential therapeutic agent for MS because of
its ability to remyelinate CNS neurons in pregnant rats afflicted with the experimental form of
MS, EAE (Gregg, Shikar et al. 2007). Most of the current treatments in MS involve the
manipulation of the immune system, as previously described.
Glial Cells
Glial cells (astrocytes, oligodendrocytes, and microglia) play a vital role in the
maintenance and survival of neurons. Oligodendrocytes play a crucial role in the survivability
and proper function of neurons. They wrap portions of their cell body around the neuron and, in
essence, squeeze out the cytoplasm, forming an insulator around the axon of the neuron know as
the myelin sheath. This allows the neuron to propagate action potentials, which are waves of
bioelectrical currents that constitute cellular communication in neurons. This myelin sheath is
the portion of the neuron that is attacked by the immune system during the onset and relapses of
MS. The suspected targets for the immune system are three proteins: MBP, MAG, and MOG.
For neurons to maintain their proper functionality, astrocytes play an equally important
role in the nervous system by supplying the neuron with nutrients (glucose). Astrocytes are
numerically the most prevalent cell in the mammalian brain (Nair, Frederick et al. 2008). They
also play a role in pH and ion balance in the CNS, as well as waste management and synaptic
transmission by mediating the uptake of glutamate and converting it to glutamine which helps to
prevent neuronal and oligodendrocyte damage (Nair, Frederick et al. 2008). It has also been
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noted that in normal rat spinal cords, astrocytes express factors such as brain derived
neurotrophic factor (BDNF), neurotrophin 3 (NT3), and nerve growth factor (NGF) -- all of
which promote the survival of neurons (Nair 2008). Astrocytes even produce factors essential
for oligodendrocyte progenitor cells (OPCs) to mature, which is essential for the remyelination
process in CNS lesions (Nair, Frederick et al. 2008). This topic is controversial because glial
scars form where MS lesions are found in the CNS. This process limits further spreading of
CNS damage by astrocyte secretion of FGF-2, causing OPCs to proliferate and survive but not to
mature, preventing the remyelination process.
Another critical function of astrocytes is the maintenance of the blood brain barrier
which, when compromised, is another marker of neurodegenerative diseases like MS because of
the influx of systemic immune factors like macrophages and T-cells. During injury or disease
states, however, astrocytes are important mediators of inflammatory responses. Astrocytes can
cause a condition known as reactive gliosis, in which a specific protein known as glial fibrillary
acidic protein (GFAP) is highly up-regulated on the astrocyte’s cell surface and is a marker used
to diagnose MS (Nair, Frederick et al. 2008).

GFAP seems to be tightly regulated as

demonstrated in experiments with knockout mice and mice overexpressing GFAP, both of which
show neurological dysfunction (Nair, Frederick et al. 2008). Astrocytes also cause the release of
pro-inflammatory cytokines like IL-1 and IL-6 and can release cytotoxic cytokines like TNF
Fas ligand (FasL), and transforming growth factor beta (TGF in response to neuronal damage
(Kaminska, Gozdz et al. 2009).
Astrocytes also express Major Histocompatibilty Complex (MHC) I and II, which
recognize specific antigen presentation by antigen presenting cells (APCs), and have the ability
to activate CD4+ and CD8+ T-cells when treated with IFN
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Although astrocytes are non-professional antigen presenting cells (APCs), they have been
documented as forming immunological synapses with T-cells and secreting multiple types of
cytokines and chemokines known to attract T-cells or cause inflammatory responses (CCL2,
CCL3, CCL5, CXCL8, CXCL9, CXCL10, and CXCL12). They also express cellular adhesion
molecules like intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule
(VCAM) which probably stabilize the immunological synapse formed by astrocyte-T-cell
interactions as well as APC-T-cell interactions in the CNS (Nair, Frederick et al. 2008). Much of
the present data is very controversial about the functions of astroglia in disease states like MS,
indicating that a very specific time progression and consequent astrocyte reaction is involved in
the disease.
Microglia have a relatively unknown normal physiological function in the brain but were
first described in 1932 by Pio del Rio-Hortega as the macrophages of the nervous system. The
main purpose of microglia in the CNS is to act as the immune cells of that system. When
activated, they can up-regulate many different types of cellular receptors and secrete multiple
factors employed by the immune system, including cell adhesion molecules, integrins,
cytokines/chemokines and their receptors, toll-like receptors, matrix metalloproteinases,
eicosanoids, growth factors, proteases, and cathepsins, just to name a few (Rock and Peterson
2006). Since microglia are the primary phagocytes of the brain and play a huge role in the
activation of immune responses in the CNS, they have been targeted as one of the primary
conductors in the pathology of MS. Gonsette (2008) has stated that one of the hallmarks of
microglial activation in MS is oxidative stress and excitotoxicity. This leads to the compromise
of the cells’ integrity and apoptosis. They also seem to be involved in some type of cellular
balancing act by being both protective and destructive at the same time. Muzio (2007) states that
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there are multi levels of functionality of microglia, from an inflammatory phase they call
“detrimental” to a protective, “non-detrimental” phase regulated by a feedback loop mechanism.
They have vast amounts of cross over with astrocytes in function but are considered to be the
main initiators and potentiators of the immune response in neurodegenerative diseases.
Gangliosides
Gangliosides are membrane bound, amphipathic molecules, with an unknown normal
function, but their role in specific pathologies has been well defined. Gangliosides consist of a
fatty acid tail, a ceramide portion, a lactose core, and a variable carbohydrate chain with sialic
acid linkages to its galactose residues. This gives the ganglioside and its various isoforms an
overall negative charge. Gangliosides seem to be evolutionarily conserved since they are found
in all vertebrates and some in-vertebrates (echinoderms), with very high homology.

Even

bacterial lipopolysaccharide (LPS) has molecules that mimic ganglioside epitopes, which is
important for the bacterium’s ability to bind to other cells and evade the host’s immune system.
The most well known example of this is the role of ganglioside GM1 as the receptor for the
cholera toxin which mediates the entry of the toxin into the cell.
While gangliosides are present in many tissue types, they occur in their more complex
forms primarily in the CNS of vertebrates.

The biosynthesis of gangliosides and their

differentiation into the more complex series of gangliosides is catalyzed by the co-activation of
the two key enzymes: sialyltransferase II (STII) and N-acetyl- galactosaminyl transferase (GNT),
as shown in Fig. 1.

If the activity of one of the enzymes is lost, the other becomes non-

functional as well (Bieberich, MacKinnon et al. 2002), resulting in the over-expression of the
most abundant ganglioside precursor, GM3, thereby causing it to build up in the cell. The
inability to differentiate gangliosides into higher order forms or metabolize them into simpler
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forms for cellular recycling contributes to multiple pathologies, including Tay-Sachs disease and
numerous forms of lysosomal storage diseases.
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Fig.1. Glycosphingolipid Biosynthetic Pathway. STII catalyzes the addition of a second sialic acid to the first
one, and GNT catalyzes addition of N-acetyl- galactosaminyl to galactose. Adapted from Essentials of
Glycobiology, 2nd edition Copyright ©2009 by The Consortium of Glycobiology Editors, La Jolla, California.
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Role of Gangliosides in Disease
The most classical neuropathology associated with gangliosides is Tay-Sachs disease. It
is caused by mutation of the hexosaminadase A (Hex A) enzyme which converts GM2 into
GM3, a genetic abnormality found mainly in people of eastern European Jewish descent. This
leads to GM2 accumulation, neuronal dysfunction, and eventually death. A similar disease
associated with gangliosides is Sandhoff’s disease. Sandhoff’s is almost identical to Tay-Sachs
but the genetic deficiency affects the beta subunit of both the Hex A and Hex B enzyme and is
more prevalent in non-Jewish populations. The disease causes the accumulation of GM2 in the
lysosomes of the cell, ultimately causing cell death. Many of the diseases involving gangliosides
exist because of a metabolic dysfunction in ganglioside synthesis and recycling resulting in the
accumulation of specific gangliosides in the CNS.
Gangliosides also act as receptors for different types of pathogens as well. The classic
example of this is the ability of cholera toxin to bind to ganglioside GM1 (Holmgren, Lonnroth
et al. 1973; Holmgren, Lonnroth et al. 1973). GM1 acts as a receptor for cholera toxin by
binding to its subunits and mediating the entry of the toxin into otherwise healthy cells.
Gangliosides also bind and mediate the entry of other viruses and bacterial toxins like botulinum,
influenza, and tetanus Mellanby, 1973 #40}. They have even become a potential target for
biological warfare because of their ability to mediate the entry of viruses and toxins into cells
(Singh, Harrison et al. 2000). This ability to mediate cellular infection and the lack of glycolipid
metabolism by genetic dysfunction has drawn attention to the importance of gangliosides in
biomedical research.
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Gangliosides in Autoimmunity
It has been reported that gangliosides also play a role in the misrecognition of cancer
cells by deactivating the T-cells.

This occurs through massive shedding of gangliosides by

tumor cells, allowing for the progression and metastasis of several types of cancers (Potapenko,
Shurin et al. 2007). It has also been shown that exogenous gangliosides can act as antagonists
against fibroblast growth factor receptors (FGFr) by binding to the COOH terminal of the
receptor causing a reduction in the viability and proliferative functions of epithelial cells
(Rusnati, Tanghetti et al. 1999).

Many studies involving MS have determined that the targeting

of the CD4+/CD8+ T-cells are specific for myelin basic protein (MBP) and myelin associated
glycoprotein (MAG) (Musse and Harauz 2007; Quarles 2007). MBP is in the subgroup of the
sialic acid-binding immunoglobulin superfamily whereas MAG may bind negatively charged
lipids on the plasma membrane portions of glial cells, specifically oligodendrocytes, which
provide the myelin sheath of neurons (Musse and Harauz 2007; Quarles 2007).
Gangliosides posses both of these characteristics; having both a negative charge and
sialic acid sugars bound to their galactose molecules. This T-cell/microglial-neuron interaction
may be mediated by the abundance of specific gangliosides found on the cell surface of antigen
presenting cells (APCs), neurons, and glial cells. This further supports the idea that gangliosides
may indeed play a role in the activation and mediation of T-cells and/or microglia in other
autoimmune diseases such as MS in conjunction with the previously mentioned roles of MBP
and MAG.
Further evidence of a link between MS and gangliosides has been provided by the
demonstration that the initial onset of the disease is similar to hypersensitivity in allergic
reactions in that activated B-cells release IgM and IgG autoantibodies against ganglioside
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glycolipids (Zaprianova, Majtenyi et al. 2004; Marconi, Acler et al. 2006). This release of
autoantibodies and their subsequent activation of T-cells may cause the breakdown of the blood
brain barrier by using matrix metalloproteinase (MMP)-9, which is characteristic of MS, and
allows for the infiltration of T-cells into the brain. This in turn causes TNF proinflammatory
cytokine secretion and apoptosis (Muroski, Roycik et al. 2008). The process by which the B/Tcells are presented with these gangliosides by APCs is still unknown, but much of the evidence
supports the idea that gangliosides do play a role in the disease.
Recent promising research has implicated a long known gylcolipid in the apoptotic
process of numerous cell types. This glycolipid is ganglioside GD3. It is believed that GD3 acts
on mitochondrial membrane transport proteins to disrupt mitochondrial membrane potentials,
which in turn causes a release of cytochrome c and caspase 3 activation (Garcia-Ruiz, Colell et
al. 2002). Garcia-Ruiz and his colleagues (2002) have also shown that ganglioside GD3 is an
important intermediate of TNF mediated apoptotic cell death. They demonstrated that TNF
secretion caused dramatic re-localization of GD3 to the mitochondria during cell death in
hepatocytes which, they concluded, occurred by neosynthesis. Melchiorri (2002) have also
reported that increased levels of GD3 caused neuronal apoptosis. Other studies have suggested
that gangliosides GM1 and GD2 may be potential targets for B and T-cells of the immune system
due to the relatively high titers of autoantibodies in the serum of multiple sclerosis patients
(Zaprianova, Majtenyi et al. 2004; Marconi, Acler et al. 2006). Some recently published papers
have contradicted the theory that GD3, along with TGF, can actually produce some angiogenic
affects by enhancing hepatocyte growth factor in glioma cell lines (Chu, Ma et al. 2007). Others
have shown that GD3 can not only cause apoptosis by ROS formation and release, but by also
inhibiting the binding of the transcription factor NF which can be used to either cause the cell
16

to survive and proliferate or go into a cell death pathway for apoptosis (Colell, Garcia-Ruiz et al.
2001). Finally, TNF receptor 1 has been reported to play a role in the negative proliferation of
hippocampal neurogenesis in adult brains of mice (Iosif, Ekdahl et al. 2006).
Sialic Acid
The constituent that makes a glycolipid a ganglioside is the presence of sialic acid. Sialic
acid is a negatively charged sugar attached to the galactose carbohydrates on the backbone of a
ganglioside. Sialic acid is the main effector for many diseases like influenza, tetanus, botulism,
and, when polysialylations occur, can protect the body from foreign pathogens, acting as part of
the innate immune system by essentially distinguishing the self from possible pathogens,
allowing for proper immune recognition (Schauer 2009). This helps to shield antigenic sites
which can weaken immunoreactivity; but in cases of lost polysialylations, could possibly lead to
autoantibody production at antigenic sites where prior bacterial and viral infections have
occurred (Schauer 2009). Sialic acids also play a role in the antagonistic effects on receptors like
(TrKA) FGF2, EGF, VEGF, LYVE-1, and B1 integrins which bind galectin-3 for anti-apoptotic
effects (Schauer 2009).
Gangliosides have the ability to bind to galectins, specifically siglec 4 (MAG4) which
plays an important role in the ability for myelin from oligodendrocytes to bind to the axons of
neurons (Schauer 2009). The gangliosides involved in this association with the myelination of
neurons are GT1b and GD1a but not GM1 or GD1b. When null mice lacking the complex
gangliosides GT1b and GD1a were observed for their neuronal competence, the neurons
displayed demyelination and axonal damage which was comparable to null mice lacking MAG
(Lopez and Schnaar 2009). Siglec-7 has a very strong association with gangliosides from the bseries including GD3, GD1b, and GT1b (Lopez and Schnaar 2009). This interaction has been
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shown to modulate natural killer cell responses and may lead to immune misrecognitions of the
self (Lopez and Schnaar 2009).
Sialic acids found on glycoproteins known as selectins have also been studied for their
involvement in the functional immune system. It has been shown that E, L, and P-selectins
preferentially bind to the tetrasaccharides sialyl-Lewisx and sialyl-Lewisa (Schauer 2009). This
allows for a point of entry for circulating lymphocytes by tethering themselves to the sialic acid
moieties of these Lewis structures leading to the internalization and invasion of multiple immune
system effector cells. TNF has also been known to increase the expression of E and P-selectins
during inflammation so this suggests a possible pathway involving sialic acid containing
molecules working synergistically with the pro-inflammatory cytokines to achieve clearance of
pathogens and apoptosis of dysfunctional cells.
Collectively, this evidence suggests a molecular mechanism in the progression of
multiple sclerosis through neuronal apoptosis. This mechanism involves activated microglia
which secrete TNF

other pro-inflammatory cytokines and neurons which express MBP,

MAG, growth factor receptors, and gangliosides.

These factors are naturally occurring in the

brain and have been previously investigated as potential mechanisms of neuronal cell death
associated with MS. Since gangliosides have a ceramide moiety that can embed itself in the cell
membrane, gangliosides can potentially affect the viability of the cell directly by interfering with
the activity of the mitochondria via release of cytochrome c, activation of multiple caspases, and
ultimately cell death. Additionally, gangliosides may reduce neuronal viability by interfering
with growth factor receptors, reducing the signal needed for cells to remain viable and ultimately
causing the neuron to die.
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The hypothesis tested by this dissertation research is that TNF instigates cell death of
brain cells by interacting with gangliosides (especially GD3) in a way that promotes proinflammatory cell cascades and inhibits pro-growth and differentiation of cell processes.
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Chapter II

VIABILITY OF NEUROBLASTOMA CELL LINES
TNF Administration With and Without Gangliosides for Viability Testing
OBJECTIVE
To explore the possibility that a pro-inflammatory cytokine, TNF, can initiate cell death
to a degree dependent on the presence of a specific ganglioside profile, my initial project was to
test the effect of TNF on a family of neuroblastoma cell lines genetically modified to alter their
ganglioside profiles. Neuroblastoma cells designated F11-A served as controls; lacking STII or
GNT, they are unable to synthesize GD3 or any more complex ganglioside. The STII F11-A cell
line consists of F11-A cells transfected with a coding insert for STII, so that GD3 can be
synthesized. The GNT F11-A cell line consists of F11-A cells transfected with a coding insert
for GNT, so that GM2 and GM1 can be synthesized, as well as all disialogangliosides, if STII is
also present (see Fig. 1).

All cells were tested for viability/cell death by the (3-(4,5-

dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

(MTS)

cell viability assay, allowing a determination of whether and which gangliosides play a role in
the signal transduction of cell death.
METHODS
F11-A Neuroblastoma cell culture and MTS viability assay
F11-A neuroblastoma cell lines (F11-A, STII, and GNT) were thawed from -140 Cº and
plated in T-25 cell culture flasks with 5ml of DMEM culture media containing 10%FBS and 1%
pen/strep. Flasks were grown to ~80% confluency and passaged to T-75 flasks containing 25ml
of complete culture media. Cells were then grown to ~80% confluency and trypsinized. Cells
were then collected in 50ml conical tubes and the trypsin was deactivated with complete media
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containing FBS. 1 ml was retained for cell counting and the rest of the cell suspension was
centrifuged at 1600 RPMs for 3 minutes to pellet the cells and the media was then poured off.
The 1ml of the retained cells was counted using only 1l of the 1ml cell suspension by
hemocytometer and the centrifuged cells were resuspended to a final concentration of 100,000
cells per 1ml. 200ul (20,000 cells) were added to their appropriate wells in a 96 well cell culture
plate and allowed to adhere for 24h. The cells were then treated with different concentrations of
TNF  and 

l of MTS

assay reagent and incubated for 1-3h. The wells were read by a spectrophotometer at absorbance
490 to determine viability.
Assessment of ganglioside pattern
After detaching with a cell scraper, cells were aspirated to achieve a fine suspension,
pooled from all flasks of each condition and centrifuged. The pellets were then resuspended and
washed twice with 1X PBS, then spun down at 5000 x g for 5 minutes to remove cellular protein
and debris. The pellets were then resuspended again in 2 ml chloroform/methanol (CM, 2:1) in 2
ml microfuge tubes and thoroughly homogenized to extract and isolate gangliosides from the cell
membrane by the method of Irwin & Irwin (Irwin and Irwin 1979). The cells were incubated at
45º C for 15 minutes and spun down again at 10,000g for 5 minutes. The supernatant was
applied to a 2 cm Unisil column pre-rinsed with 2 ml of CM (2:1) and flow-through then
reapplied to the column. The non-gangliosides were be eluted with a 2 ml chloroform/methanol/
water (CMW, 65:25:4) rinse followed by elution of the gangliosides with 1 ml CMW (30:30:10).
Gangliosides were eluted into clean, labeled 2 ml microfuge tubes and dried down by vacuum
desiccation. Samples were resuspended into 25 l of CM (2:1) and spotted on 5 mm lanes on
HPTLC plates.

The plates were ran in an organic solvent system containing CMCaCl 2
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(50:40:10) to separate gangliosides of different polarity, based on their sugar and sialic acid
contents. Plates were removed, dried, sprayed with resorcinol HCl, and placed on a pre-heated
tempblock at 100 Cº for 20-25 min to visualize the bands. Gangliosides were identified by comigration on the same plate with standards obtained from Matreya, Inc. (Pleasant Gap, PA).
RESULTS
Isolated F11-A cells did not express any complex gangliosides, while STII and GNT
expressed complex gangliosides according to the function of the transfected enzyme (Fig. 2).
STII cells did express GD3 (denoted by the red box), while GNT cells expressed
monosialogangliosides and GD1a, but none of the more complex gangliosides for which GD3 is
a required precursor.

Viability of the F11-A cells lacking STII and GNT enzymatic activity was substantially
lower than those cells transfected with genes to code for the enzymes (Fig. 3). When treated with
0.5 or 1.0 M TNFfor 24h, STII cells, which have GD3, did in fact show a significant
reduction in viability, while GNT cells showed only a trend (p<0.08) toward a reduction in
viability at the highest concentration of TNF (Fig. 3).
.
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Fig. 2. HPTLC plate of F11-A, STII, and GNT cell lines for ganglioside expression. ~18,000,000 F11-A,
12,000,000 GNT, and 10,000,000 STII neuroblastoma cells were grown and gangliosides were isolated to obtain
HPTLC banding patterns for each cell type. Aliquots of gangliosides (5 g for standards) were spotted in each lane
and developed in a solvent of CM0.2%CaCl2 (50:40:10), then visualized with resorcinol reagent. Standards
consisted of monosialogangliosides (GM), disialogangliosides (GD) and mixed brain gangliosides (MBG).
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Fig. 3. Viability of F11-A, STII, and GNT neuroblastoma cell lines treated with variable
concentrations of TNF. 20,000 cells from each line were plated in 96 well cell culture plates
and treated with 0.2M TNF for 24h. The significance of differences in viability within the
two altered cell lines compared to wild type control (WT) cells was assessed by Tukey’s multiple
comparison test, with n=6 in all cases. *p<0.01, **p<0.001, p<0.05, p<0.001
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DISCUSSION
The evidence that gangliosides play a role in cell death is continuing to mount. One way
to test this hypothesis is to remove the gangliosides from the cell and try to stimulate the cell to
undergo cell death by the administration of a pro-inflammatory cytokine like TNF. One of the
unique attributes of F11-A neuroblastoma cells is their lack of the enzymes STII or GNT, which
means they should only express ganglioside GM3.

In conjunction with having F11-A

neuroblastoma cells, we have two other neuroblastoma cell lines that have been transfected with
either enzyme, STII or GNT, both of which express a unique and distinct ganglioside banding
pattern (Fig. 2).
This family of neuroblastoma cells allowed me to look at the possible association
between specific gangliosides and TNF, essentially acting as a knockout experiment for
viability determination. Though substantially lower in viability than the cells expressing STII or
GNT activity, F11-A cells treated with the varied concentrations of TNF
1.0M showed no noticeable decrease in viability.

M-

On the other hand, F11-A cells transfected

with the STII gene showed a significant decrease in viability when stimulated with 0.5 or 0.1M
TNF for 24h, compared to untreated, STII transfected F11-A neuroblastoma cells and STII
transfected cells treated with 0.2M TNF (Fig. 3.) This is probably due to the increased
amounts of GD3 brought on by the STII enzyme, which specifically adds a sialic acid residue to
the precursor ganglioside, GM3. This suggested that gangliosides higher than GM3 may play a
role in apoptosis when stimulated with a pro-inflammatory cytokine like TNF
.As for the GNT transfected F11-A neuroblastoma cells, there was a tendency toward
decrease in viability at the highest concentration of TNFbut this cannot be considered
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significant (p<0.08). Thus, in the absence of GD3 or its catabolic precursors, GD1b and GT1b,
no significant effect of TNF is evident.
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Chapter III

VIABILITY OF MIXED BRAIN CELL CULTURES
Experiment #1: Effect of Gangliosides and TNF on Viability of Primary Brain Cells in
Culture
OBJECTIVE
A cell culture system was established in order to determine whether individual
gangliosides play a role in cytokine-mediated death of brain cells. The use of primary brain cell
cultures represents a more physiologically relevant situation, as opposed to immortalized cells,
like PC12 cells, or the neuroblastoma (F11-A) cell lines used in the first experiment.
Numerous studies have established that GD3 is a critical factor in apoptosis, but the same
role for other gangliosides, with their different ceramide moieties and carbohydrate chains, has
not been investigated. A stable, more physiologically relevant cell culture system was needed in
order to study the mechanisms thought to be involved in neurodegeneration causing neuronal
death. The purpose of this experiment was to determine which gangliosides, in the presence or
absence of TNFα, contribute to cell death of primary brain cells in culture. The MTS viability
assay revealed that TNF and GD3, but not GD1b or GM1, caused substantial cell death in this
in vitro system.
METHODS
Primary Cell Culture
Cultures of primary brain cells were established from pooled brain sections removed
from post-natal day 1 (PND1) Sprague Dawley pups following quick decapitation. Under sterile
culture conditions, cortical and hippocampal sections were dissected out and digested by 1mg/ml
papain in 1.1mM EDTA, 0.067mM mercaptoethanol and 5.5mM cysteine-HCl. Tissues were
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triturated by Pasteur pipette and the supernatant removed and centrifuged at 1000 RPMs for 2
minutes. The supernatant was then removed, and fresh Neurobasal (Invitrogen) medium
containing 5ng/ml FGF, B27 supplement, 0.5mM glutamine, and 0.01% pen/strep was added to
the cultures. The cells were finally resuspended to 1 x 10 6 cells/ml, added to T-25 Primaria
(BD Falcon) flasks with a total volume of 5-6 mls of complete Neurobasal media, and incubated
at 37° C under 5% CO2 and 90% humidity.
Ganglioside and TNF administration
Preliminary experiments were conducted in an attempt to reproduce the existing and
sometimes controversial evidence that gangliosides are directly involved in neural cell death.
Wells were exposed initially to mixed brain gangliosides (MBG), TNF, and varying
combinations of both together in a concentration gradient fashion (see Fig. 4 for plate setup).
Mixed brain gangliosides were suspended in 10-fold dilutions, ranging from 10g to 0.1g,
while TNF treatments were serially diluted 10-fold to a final concentration range of 1M to
0.01M .
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Fig. 4. Plate setup for performing Ganglioside-TNF
Wells contained ~100,000 cells and
were treated with either 10g, 1g, or 0.1g MBG in combination with 1M, 0.1M, or 0.01M TNF for 24h.
Rows represent TNFconcentrations while columns represent ganglioside concentrations.
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A second assay tested wild type controls and positive controls for cell death against 10
fold dilutions of GD3, from 1.6nM - 160, with a constant TNF

nM) in

order to determine a dose response effect for GD3 (Fig. 6a). In parallel, another plate was set up
with the treatment conditions reversed -- 10 fold dilutions of TNF sta
containing a constant GD3 concentration of 160M (Fig. 6b).
Later experiments involving gangliosides GD3, GD1b, and GM1 were tested individually
at 160M in 24 well plates containing ~100,000 neurons per well. Each ganglioside type at
it’s160M concentration was tested in combination with 0.2M TNF
containing cells but neither gangliosides nor TNF provided wild type controls.

Three

additional wells contained cells to which lysis buffer was added to provide a baseline measure
for total cell death. Figure 7 shows the time courses study using specifically 160M GD3 in
combination with 0.2M TNF for 24, 48, and 72h.
Viability Assay/ Determination of Cell Death
Cell viability was assayed using 20l of the MTS cell proliferation assay (Promega) on
100,000 primary neurons/well in a 24 well plate. Cells were incubated for 24h in complete
Neurobasal medium in a total volume of 0.5ml per well. Plates were then removed from the
incubators; 20 l of MTS reagent were added to a total volume of 200l, and the cultures were
allowed to incubate for 2-4h. The solutions were then removed from the 24 well plates and
transferred to 96 well plates and read at an absorbance of 490 nm, which provided a measure of
cell viability.
This approach enabled us to test the effect of varying amounts and types of gangliosides
with variable amounts of TNFα on (a) viability of brain cells in culture, and (b) the ganglioside
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profile of the surviving cells (described later). This enabled us to determine if gangliosides were
involved in the initiation of cell death.
RESULTS
Overall, exogenously administered gangliosides cause a significant decrease in primary
brain cell viability (Fig. 5-7).
Within the concentrations tested for either mixed brain gangliosides or TNF , the effect
was not dose dependent, (Fig. 5). Ganglioside GD3 also depresses viability to essentially the
same degree at all concentrations tested in combination with TNF
). When primary brain cell cultures were treated with a
constant 160M GD3 concentration in combination with 10 fold dilutions of TNF(200nM2pM), there was a significant decrease in viability when compared to wild type cells but not
between the different combinatorial treatment groups.
After 24h, cell viability was significantly reduced by GD3+TNF(Fig. 7a). After 48h,
GD3 and TNF alone, as well as in combination, significantly reduced viability (Fig. 7b).
However, after 72h no significant reduction in cell viability was seen in response to all treatment
conditions.
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Fig. 5. Viability of primary brain cell cultures treated with mixed brain gangliosides (MBG) and TNF.
100,000 primary brain cells/well in 24 well culture plates were treated with 0, 4.7-6.5M, 46-64M, and 466646M
M TNF for 24h. The effect of MBG concentration was
assessed relative to cells untreated by MBG within each concentration of TNFby One-Way ANOVA with Tukey’s
Multiple Comparison Post Test, with n=6 for each independent treatment. *p<0.01, **p<0.001
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Fig. 6. Dose response for MTS viability assay for GD3+TNF. 100,000 primary brain cells/well were treated in
24-well culture plates for 24h with (a) constant 0.2M TNF concentration in conjunction with varied
concentrations of ganglioside GD3 ranging from 0.0016M to 160M, or (b) with a constant 160M GD3
concentration with varied concentrations of TNF
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test, with n=3 independent experiments. *p<0.05 **p<0.01, ***p<0.001
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Fig. 7. Effect of ganglioside GD3 and TNF administration on viability of primary brain cells over a
72h time course. 100,000 primary brain cells/well in 24 well culture plates were exposed to 160M
GD3+0.2M TNF for (a) 24h, (b) 48h, or (c) 72h Bars represent mean +/- s.e.m. The significance of
differences across treatments was analyzed by One-way ANOVA, with Tukey’s multiple comparison test for
evaluating differences between specific treatments. *p<0.05,**p<0.01,***p<0.001, compared to WT;
p<0.05, compared to GD3.
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DISCUSSION
Much evidence has appeared in the past decade suggesting that neuronal cell death is
mediated in part by gangliosides, specifically GD3, or by some of the biosynthetic/metabolic
pathways involved in ganglioside biosynthesis.

Previous research has suggested that GD3

affects neuronal viability via mitochondrial pathways by (1) increasing the overall endogenous
pool of GD3 within the neuron through the release of ROS that cause caspase activation, and by
(2) activation of the specific sialidase enzyme Neu4L, which is mitochondrially located and brain
cell specific (Garcia-Ruiz, Colell et al. 2002; Melchiorri, Martini et al. 2002; Hasegawa, Sugeno
et al. 2007). A relatively easy way to analyze cell viability is by the MTS assay. If gangliosides
and/or TNF do cause a reduction in cell viability, MTS assays would be a fast way to obtain
data for further hypothesis testing.
The literature states that the critical micelluar concentration (CMC) for disialogangliosides in an aqueous solution is in the range of 10ˉ6 M (Ulrich-Bott and Wiegandt 1984)
but micelles are involved in direct interactions with cells and may interact in three different ways
with their cellular counterparts (Schwarzmann 2001).

Most studies have used exogenous

gangliosides above their critical micelle concentration, ranging from molar concentrations at
10M, to weight to volume amounts at 50g/ml and higher in 6 well, 60mm2, and 100mm2 cell
culture plates (Melchiorri, Martini et al. 2002; Simon, Malisan et al. 2002; Jou, Lee et al. 2006).
The first test combined 0, 4.7-6.5M, 46-64M, and 466-646M of mixed brain
gangliosides with 0.01, 0.1 and 1.0M TNF

-incubated for 24h to test whether gangliosides

and TNF could indeed reduce the viability of primary mixed brain cells in culture. The
experiment was designed (Fig. 4) to determine if there was any interaction between gangliosides
and TNF. Overall, the MBG caused a significant loss of viability in all cultures treated with
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and without TNF. The results showed that (1) there is no media induced interaction with the
MTS assay and (2) cell viability is significantly reduced primarily due to MBG rather than TNF
even when both substances are combined in any combination (Fig. 5). This also showed that
there is no optimal concentration for ganglioside mediated cell death within the range tested,
since all concentrations killed the primary brain cell cultures relatively equally (no significant
differences between combinatorial conditions) when compared to wild types. Overall, in this
experiment using MBG, there seemed to be an increase in the viability of the primary brain cell
cultures treated with varied amounts of TNFalone.
We then decided to test a concentration range of the implicated cell-death mediator GD3
ganglioside, ranging from 1.6 nM to 160 M based on the vast array of concentrations tested
above the CMC stated in the literature, and lack of lower concentrations tested, while using a
constant TNF concentration that would be within the range showing a decrease in viability
according to the first MBG experiment (Fig. 5., 0.2M TNF). There was a significant decrease
in viability in all conditions when compared to the wild type, but there was NO SIGNIFICANT
decrease in viability amongst the 10-fold dilutions series of ganglioside GD3 conditions with a
constant TNF concentration of 200nM (Fig. 6a). The opposite holds true for 10 fold dilutions
of TNF ranging from 2pM-200nM with a constant GD3 concentration of 160M (Fig. 6b).
In an attempt to determine if GD3, but no other ganglioside, decreases brain cell viability,
more primary brain cell cultures were harvested and grown under the previously described
conditions, and treated with ganglioside GD3, GD1b, and GM1 in the presence of 0.2M TNF
for 24h.
GD3 exposure showed a trend toward reducing cell viability slightly more strongly than
GD1b or GM1, but the difference was not statistically significant. Subsequent experiments were
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carried out using GD3 only, while both GD3 and GD1b were used in the gene expression studies
in the next section.
Fig. 7a shows that after 24h, the only condition that significantly reduced viability was
the combination of GD3 and TNF After 48h, all conditions caused a significant reduction in
viability when compared to the untreated wild type primary brain cells (Fig. 7b). After 72h,
GD3 alone appeared to reduce viability, but the different was not statistically significant (Fig 7c).
These data give support to the possibility that gangliosides, specifically GD3, can alter
primary brain cell viability. But GD3 in not normally expressed in the adult mammalian brain
unless GD3 expression is up-regulated during pathological conditions. This increase in GD3
could be due to an increase in biosynthetic enzymatic activity needed to increase the overall
endogenous ganglioside pools, to an increase in glycosidase enzyme activities that modify
complex gangliosides to simpler forms like GD3, or to the neosynthesis of GD3 by the brain
cells specifically for its role in cell death pathways. This led to a test of whether or not TNF
causes an increase in the mRNA expression of the biosynthetic enzymes responsible for
ganglioside biosynthesis, STII and GNT.

Experiment #2 qPCR Analysis of Ganglioside Biosynthetic Enzyme GNT After TNF
Administration on Primary Brain Cell Cultures
OBJECTIVE
The ability of the pro-inflammatory cytokine, TNF, to affect ganglioside biosynthesis
was tested by analyzing its effect on the gene expression of GNT, which converts GD3 to GD2,
and STII, which converts GM3 to GD3 in primary brain cell cultures.
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METHODS
Primer Design and qPCR
To obtain a realistic measure of inter-animal variation, total RNA was extracted from
each regional sample of individual rats. mRNA was then reverse transcribed into unlabeled
cDNA templates using the Verso cDNA Kit (ABgene, Thermo Scientific). Specific forward
and reverse primers for candidate genes were designed using Primer Designer™, Version 2.0
(Scientific & Educational Software), and synthesized by IDT, Inc. (Coralville, IA).

The

FastStart SYBR Green Master® (Roche Diagnostics) fluorescent labeling kit and custom primers
(0.4 mM) were used to perform qPCR using the iCycler™ (Bio-Rad) and the following protocol:
40-60 cycles, each consisting of 30 sec for melting, 30 sec for annealing, and 20 sec for
elongation. All samples were run in duplicate along with a standard curve to calculate copy
numbers of mRNA for each gene, and normalized to ribosomal 18S RNA as an internal standard.
RESULTS
There was a significant increase in GNT expression but not in STII when TNF was
applied to primary brain cells in culture for 24h (Fig. 8).
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Table 1. Sequences of forward and reverse primers used for qPCR
Gene
Primer
______________________________________________________________________
GNT
F’
5’- GTA ACA CTG GTT GGT TGT
R’
5’- CTT GAT GTC CGC CTG TC
STII
F’
5’- CAA CGA GAA GGA GAT TGT GC
R’
5’- CTG AAG AGA CTG GCT GAC G

S T II

G NT
20

20

WT
R elative E xp r essio n

R elative E xp r essio n

Oligo

*

10

TNF 

10

0

0
WT

WT

TNF 

TNF 

Fig. 8. Effect of TNF
primary brain cell cultures. 1,000,000 primary brain cells were treated with 0.2M TNF for 24h and mRNA was
isolated for qPCR analysis. The graph represents the expression of the ganglioside biosynthetic enzymes GM3/GD3
synthase (STII) and GD3/GD2 synthase (GNT) in WT and TNF treated primary brain cell cultures. Statistical
analysis was performed by Mann-Whitney U test and significant values are represented by * (p<0.0003, n=8).
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DISCUSSION
If the hypothesis that TNF and gangliosides act together in some way to initiate cell
death is correct, then TNF should affect the gene expression of STII and/or GNT. The relative
gene expression of STII was not affected when TNFtreated cultures were compared to normal
wild type cultures. There was, however, a significant increase in the relative gene expression of
GNT when TNF -treated cell cultures were compared to wild type cultures (Fig. 8).

Since

most of the gene expression data (Section IV) show that GD3 and GD1b have similar effects on
primary brain cell cultures, it is possible that GD1b may have a similar effect to that of GD3. It is
possible that more time is needed to increase the overall pool of gangliosides, especially if STII
and GNT work in conjunction with and activate one another to increase more complex
gangliosides such as GD 1b, in order to increase endogenous GD3 by glycosidase cleavage of
GD1b. GD3 is not normally expressed past gestational development of the brain and cannot be
found in the adult brain, unless reactive gliosis or brain injury occurs, probably due to the
concerted actions of these enzymes (STII and GNT). Thus it is plausible that cytokine
stimulation increases ganglioside biosynthesis first, like the increase seen in GNT, and then
therefore initiates a cell death cascade causing an increase in the normally expressed
gangliosides like GD1b first, which may be needed to increase the overall pool of gangliosides
that could eventually be modified by glycosidase cleavage, thus causing a downstream effect by
increasing the cellular amounts of GD3. This could explain why STII- transfected neuroblastoma
cells showed an immediate and significant decrease in viability when exposed to TNF for 24
hours due to their already present GD3 supply and unneeded use for enzymatic modifications to
produce GD3 while GNT transfected neuroblastoma cells had a smaller but marked decrease in
viability but nothing that was significant (Fig. 3). GNT transfected cells do contain two isoforms
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of GD1a and smaller amounts of GD1b which may account for the noted reduction in viability in
these cells, but it is possible that more time is needed to see similar, significant decreases in
viability like those observed in STII cells.

Experiment #3 Analysis of Ganglioside Profiles by Mass Spectrometry
OBJECTIVE
The ganglioside content of brain cell cultures following exposure to exogenous
gangliosides and TNF independently was analyzed in order to observe if any changes are made
to the endogenous pools of gangliosides that may be associated with cell death.
PROCEDURE
Cell culture
Brains were taken from PND1 rat pups by live decapitation as previously described.
Cortex and hippocampus were dissected out of each brain and digested in 1mg/1ml of papain for
30 minutes at 37 Cº.

Cells were then transferred to 10ml of complete Neurobasal media

containing 1ml B27, 1 ml Pen/Strep, 100l glutamine, and 100l FGF with as little papain as
possible and titurated by pasteur pipette aspiration. The cell suspension was allowed to sit for 1
minute and then the supernatant was transferred to a new 50ml conical tube. 1ml of cell
suspension was retained for counting by hemocytometer while the rest of the cell suspension was
centrifuged at 1100 RPM for 3 minutes. The cells were then resuspended to a concentration of
1,000,000 cells per 1ml and plated into 6 well Primeria™ plates at 1,000,000 cells per well.
Cells were allowed to grow until they were differentiated and then treated with 3M GD3,
GD1b, 200nM TNF and controls were untreated, primary brain cell cultures. Cell cultures

41

were incubated for 24h and then collected for ganglioside separation and analysis by mass
spectroscopy.
Ganglioside Extraction
Approximately 1,000,000 primary cells were removed by scraping, rinsed with 2ml of
phosphate buffered saline (PBS), and centrifuged at 13,000 RPMs. All PBS was removed and
the cells were lyophilized. Lipids were extracted 3× with chloroform/methanol (2:1, v/v). The
suspensions were centrifuged for 30 minutes at 1,764 g and the supernatants were dried down
under a stream of nitrogen. Sonication combined with Folch’s partitioning four times with 1ml
of each polar solvent: (1) 1:1 chloroform-methanol, (2 and 3) 55:25:20 isopropanol-hexane-water
with removal of the upper phase by aspiration before use, and (4) 1:1 chloroform-methanol)) was
then used to separated neutral and negatively charged glycosphingolipids. The supernatants
were removed after centrifugation and dried under nitrogen gas.

The samples were then

resuspended in 5ml 100% methanol.
Separation of Gangliosides
Samples were run through a SAX column that was previously washed with 4ml
methanol, 2ml 80% acetonitrile/0.05% trifluoroacetic acid, and equilibrated with 10ml 100%
methanol. The 5ml samples were applied to the column and rinsed with 6ml 100% methanol,
after which they were eluted with 6 ml of 250mM ammonium acetate in 100% methanol.
Samples were dried under nitrogen stream and desalted in a 3ml reverse phase cartridge
(Discovery DSC-18, Supelco, Bellefonte, PA, USA). Cartridges were washed with 4ml 100%
methanol, equilibrated with 5ml deionized water, and the samples were loaded in 5ml 0.1M KCl.
Cartridges were then washed with 10ml water and then eluted with 10ml methanol, after which
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they were dried down under nitrogen stream. Samples were then permethylated, dried, and
resuspended in 200l 100% methanol in preparation for mass spectrometry.
RESULTS
Ganglioside profiles in the mixed brain cell cultures treated with exogenous GD3, GD1b
and TNF give no indication of altered overall endogenous ganglioside pools (Fig. 9). These
samples were too small and had some contaminants within them.
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Fig. 9. Mass Spectrometry of gangliosides from primary brain cell cultures left untreated (wild type, WT) or
Treated with TNF, GD3, or GD1b. 1,000,000 primary brain cells were treated with 0.2M TNF and 3M
GD1b/GD3 for 24h. Gangliosides were extracted by Folch’s partitioning and purified by a strong ion exchange
column. Samples were permethylated and run through a QTOF mass spectrometer.
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DISCUSSION
Gangliosides are constantly being recycled and modified at differential rates ranging
from a few hours to about 48h. It is possible that brain damage or injury causes the release of
gangliosides from other glial types, which in turn, modulate neuronal apoptosis. Nothing can be
determined by the mass spectrometry data due to small sample amounts and contamination found
within these samples. Future studies should included comparative standards for identification of
specific ganglioside species and the use of more advanced mass spectrometers that can
discriminate against background and possible contaminants.
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Chapter IV

GENE EXPRESSION IN PRIMARY BRAIN CELLS IN CULTURE
Experiment # 1: Microarray Analysis of Primary Cultures Exposed to GD3, GD1b, and
TNF.
OBJECTIVE
The objective of these experiments was to determine which additional pathways and
changes in gene regulation may be involved in the ganglioside-induced apoptotic pathway by
using microarray analysis. Potential genes of interest were identified by their relative level of
response in the cell during ganglioside-induced cell death using microarrays specifically targeted
for cell signaling, cytokines, chemokines, and apoptosis. This yielded a number of novel and
relevant targets involved in pathways of neural cell death governed by gangliosides that have yet
to be identified.
At the completion of the cell viability experiments total RNA was collected from the
cells, and cRNA probes were synthesized for microarray analysis of potential genes that may
play a role in the apoptotic pathway. Those genes indicated as being differentially expressed by
microarray assay were quantified by qPCR to determine their relative difference in mRNA
expression over all conditions.

The results suggested potential target genes for additional

experiments on the apoptotic pathway possibly involved in neurodegenerative diseases, and
enabled formulation of a hypothetical pathway involved in ganglioside mediated cell death.
METHODS
Microarray analysis of potential mechanisms and cRNA Probe Synthesis
Microarrays from SABioscience® for Chemokines and Receptors (ORN-22) and for
Inflammatory Cytokines and Chemokines (ORN-11) were used to determine key role players in
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this specific form of cellular death. One million primary brain cells were exposed to 3 M
exogenous GD3 and GD1b in separate wells, while other wells were exposed to only 0.2M
TNF for 24hrs. Total RNA was isolated using the RNAqueous Micro (Ambion) kit and
quantified using a Nanodrop® (ThermoScientific) spectrophotometer.

RNA was reverse

transcribed to cDNA which was then used to synthesize biotin-labeled cRNA probes using the
Tru-Amp Labeling Kit (SABioscience). Labeled probes were then hybridized overnight to the
microarray membranes and visualized by biotin excitation using the GEArray Chemiluminescent
Detection Kit (Superarray). Images were taken of the arrays and transformed into TIF files.
The images were scanned and normalized by Quanitity One™ according to the housekeeping
genes at the bottom of the arrays. Percent differences were calculated and target genes were
identified by their highly differential expression between control and treatment groups. This
survey experiment was intended to identify potential molecular targets involved in ganglioside
induced cell death.
RESULTS
Preliminary results (n=1) showed that GD3 and GD1b could in fact induce or repression
the expression of multiple genes over a 24h incubation period (FGFR3 -21% for GD3, -19% for
GD1b; TGFB2 -27% for GD3, -21% for GD1b) (Fig. 10) on the ORN-11 micro array. The
preliminary data for the ORN-22 microarray also showed that GD1b could increase SCYE1 and
NF1 by 21% while increasing RDC1 by 30% over a 24h period (Fig. 11). Later studies were
conducted in order to increase our sample size using the ORN-11 micro arrays (n=2). Control
and treated cell cultures containing 1,000,000 primary brain cells (n=2) were lysed and the
mRNA was isolated and collected for micro array studies. The ORN-11 micro array studies
indentified 13 potential genes by housekeeping gene normalization using Quanitity One™, that
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were affected by GD3, GD1b, or TNF treatments (Fig. 12 & Table 2). The genes identified
were: bone morphogenetic protein 2 (BMP2), transforming growth factor beta 2 (TGFB2),
fibroblast growth factor 13 (FGF13), FGF receptor activating protein 1(FRAG1), transforming
growth factor beta inducible early growth response (TIEG), interleukin 1 receptor 1 (IL1R1),
chemokine ligand 2 (CCL2), interleukin 3 receptor alpha (IL3RA), interleukin 4 receptor (IL4R),
interleukin 18 (IL18), Interferon-related developmental regulator 1 (IFRD1), Macrophage
Inflammatory Protein-3 (MIP3A), and CCAAT/enhancer-binding protein beta (CEBPB).
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WT

GD3

GD1b

Fig. 10. Preliminary ORN-11 inflammatory cytokine microarray. The black arrows are
indicating the relative gene expression of FGFR3. A 21% decrease was observed in the GD3
condition while the GD1b condition showed a 19% decrease in FGFR3 when compared to the
WT control. The red arrows indicate the relative expression of TGFB2. A 27% decrease was
seen in the GD3 condition whereas the GD1b condition observed a 21 decrease in the relative
gene expression when compared to the WT control. Overall, both GD3 and GD1b showed a
decrease in most of the genes but were too small of a decrease to be considered significant
with an n=1.
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Fig. 11. Preliminary ORN-22 chemokines and receptors microarray. Microarray analysis of WT
and GD1b treated primary neurons. Primary neurons were treated with ganglioside GD1b for 24hrs
and their RNA was extracted for probe synthesis. The results were analyzed by normalizing the
intensities of the scanned arrays and percent differences were performed. The black arrows are
indicating the relative gene expression of NF1. A 21% increase was observed in the GD1b treated
neurons when compared to the wild type condition. The red arrows are indicating the relative gene
expression of SCYE1 and a 21% increase was observed when compared to the wild type. The blue
arrows indicate the relative gene expression of RDC1and a 30% increase was shown when compared to
the wild type.
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Fig. 12. Targeted ORN-11 microarrays for inflammation. Black arrows indicate CCL2, red arrows indicate
MIP3A, and green arrows indicate FGF13. N=2 for each condition, housekeeping genes were normalized by
Quanitity One™ (bottom row) and percent changes were calculated for all genes. Genes with the biggest percent
difference between treatment conditions were chosen for qPCR quantification.
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Table 2. Selected gene expression changes in primary brain cell cultures exposed to
exogenous gangliosides and TNF

Treatment Compared to WT
GENES
Growth
and
Differentiation
BMP2
TGFB2
FGF13
FRAG1
TIEG
Immune System
Effectors
IL1R1
CCL2
IL3RA
IL4R
IL18
IFRD1
MIP3A
Transcription
Factors
CEBPB

GD1b

GD3

TNF

16%
-4%
11%
-1%
11%

33%
-4%
-39%
21%
-15%

-47%
-33%
-43%
-59%
-44%

11%
-34%
-5%
0%
-3%
2%
30%

1%
-12%
-17%
4%
-2%
-10%
31%

-16%
73%
-44%
-30%
-39%
-61%
176%

7%

-12%

-30%

Images from microarrays shown in Figs. 10-12 were quantified by scanning densitometry. This table represents
micro arrays from Fig. 12. Numbers represent intensity differences reflective of mRNA levels relative to level of
mRNA expression in WT controls. Results are based on one microarray membrane or the average of two
membranes. Red text indicates genes that were significantly different when quantified by qPCR.
.
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Discussion
Based on these microarray results, 13 potential genes were picked for follow-up
validation using qPCR (Table 2).

The criterion for picking these genes was differential

expression of at least 30% in at least one condition compared to controls.

The

use

of

microarrays was an important tool in the mining for potential genes involved in gangliosidemediated cell death but was a less accurate method of analysis. Samples were pooled together
which incorporates multiple animals, giving an overall look at changes in gene expression and
allowed for enough mRNA to synthesize a probe for the microarray analysis. For Figures 10 and
11, the sample size was n=1, which isn’t a big enough sample size to justify our findings. Figure
12 did have a sample size n=2 for each condition which gave a better indication of changes in
gene expression. Microarray analysis is an excellent and fast method for finding large amounts
of potential genes but does have some drawbacks.
densitometry, which is relatively imprecise.

Microarrays are quantified by relative

If the microarrays membranes haven’t been

thoroughly washed, saturation and non-specific binding can become an issue when trying to
quantify the relative densities of the microarrays. Another big drawback is the labeling process.
This step is light sensitive and any exposure to light, or the length of time before scanning the
membranes, can reduce the signal and give an inaccurate reading. This is what led to the use of
qPCR, or quantitative polymerase chain reaction, which is an accepted method for microarray
quantification. This gave a more precise look at the changes in gene expression, in real time,
with better means of normalization.
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Experiment #2-qPCR Quantification of Differential Gene Expression in Primary Brain
Cells Exposed to GD3, GD1b, and TNF
OBJECTIVE
The goal of this experiment was to quantify the differential expression of candidate genes
isolated by microarray analysis in primary brain cells treated with gangliosides or TNF using
qPCR analysis.
PROCEDURE
Primer Design and qPCR
To obtain a realistic measure of inter-animal variation, total RNA was extracted from each
regional sample of individual rats. mRNA was then reverse transcribed into unlabeled cDNA
templates using the Verso cDNA Kit (ABgene, Thermo Scientific). Specific forward and
reverse primers (Table 3) for candidate genes were designed using Primer Designer™, Version
2.0 (Scientific & Educational Software), and synthesized by IDT, Inc. (Coralville, IA). The
FastStart SYBR Green Master® (Roche Diagnostics) fluorescent labeling kit and custom primers
(0.4 mM) were used to perform qPCR using the iCycler™ (Bio-Rad) and the following protocol:
40-60 cycles, each consisting of 30 sec for melting, 30 sec for annealing, and 20 sec for
elongation. All samples were run in duplicate along with a standard curve to calculate copy
numbers of mRNA for each gene, and normalized to ribosomal 18S RNA as an internal standard.
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Table 3. Sequences of Forward and Reverse Primers Used For qPCR
Gene
Primer
______________________________________________________________________
BMP2
F’ 395
5’- CAT CAC GAA GAA GCC ATC
R’ 801
5’- GAC CTG CTA ATC CTC ACA
CCL2

F’ 84
R’ 362

5’- CTC TGT CAC GCT TCT G
5’- CTC ACT TGG TTC TGG TC

CEBPB

F’ Pub Seq
R’ Pub Seq

5’- ACT TCC TCT CCG ACC TCT TC
5’- CAG CTT GTC CAC CGT CTT CT

IL3RA

F’ 718
R’ 828

5’- CTG TGC TGG AGG AAG TC
5’- CTC GCA GTT CTC AGG TG

FGF13

F’ 1365
R’ 1606

5’- CCT CTC CTT CCT ACT GTC C
5’- CAA TGC CAC TGT TCC AC

FRAG1

F’ 1077
R’1299

5’- CTC AAT GTG GTG GAG AAC
5’- CCG AGA AGA AGG AGA TGA AG

IFRD1

F’ 427
R’ 1048

5’- GAA GAC AAG ACA GGC AGC
5’- GTC ACT CTC CAT TCC TC

IL18

F’ 221
R’ 296

5’- GAA CAG CCA ACG AAT CC
5’- GTC ACA GCC AGT CCT CCT AC

IL4R

F’ 2677
R’ 3012

5’- GCT GAG GTC TGT GCT AAG G
5’- CTA TGC CAG GAC TGC TGT G

MIP3A

F’ Pub Seq
R’ Pub Seq

5’- AGA GTT TGC TCC TGG CTG
5’- GGA TGA AGA ATA CGG TCT GTG

TGFb

F’ 1830
R’ 2072

5’- CAG CAA CAA CAG CCA C
5’- GCA GAG CAA TAC AGA GG

TEIG

F’ 1121
R’1451

5’- CCT TGC CTG TCA TCT G
5’- GTC TTG CCA CAT CCT G

IL1R1

F’ 1766
R’2091

5’-GCC AGT CAT CTG AAG AGC
5’-GCC AAG TGG TAA GTG TGT C
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Oligo

RESULTS
13 genes were identified by micro array analysis and primer sequences were designed for
qPCR analysis (Table 3).

Of the 13 genes tested, 6 showed significant changes in their

expression in one or more treatment groups (13a-f). The expression of two genes, MIP3a and
IL1R1, was up-regulated in cells treated with either GD3 or GD1b, but not by TNFConversely,
the expression of FGF13 was down-regulated in cells treated with either GD3 or GD1b, but not
by TNF.
The expression of two other genes, FRAG1 and IL3RA, was down-regulated in cells
treated with GD3 but not GD1b, and up-regulated by treatment with TNF
Cells subjected to all three treatments – GD3, GD1b, and TNF –
regulation of the gene for CCL2. The effect was much stronger, however, in response to TNF
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FIG. 13a. Effect of ganglioside GD3 and GD1b, and of TNF, on gene expression of MIP3A. Cerebral tissue
from rats 1-4 days postnatally was disrupted and cultured to a concentration of 1 x 10 6 cells per 2ml well, then
exposed for 24h to 5 g/ml gangliosides (3m GD3 or 3m GD1b), or to 200nm TNF. Total RNA was extracted,
mRNA was reverse-transcribed to cDNA, which was quantified for relative expression of individual genes by qPCR
bars show means ± s.e.m for 8 experiments/treatment. Differences by unpaired t-tests were significant relative to
untreated wild-type (WT) cells (WT *p<0.002, **p<0.0001; TNFp
p<0.0001; n=8 for all conditions).
FIG. 13b. Effect of ganglioside GD3 and GD1B, and of TNF, on gene expression of FGF13. Experimental
conditions as in Fig. 13b. Differences by unpaired t-tests were significant relative to untreated wild-type (WT) cells
(WT* p<0.0001, TNF p<0.0001; n=8 for all conditions).
FIG. 13c. Effect of ganglioside GD3 and GD1B, and of TNF, on gene expression of IL1R1. Experimental
conditions as in Fig. 13c. Differences by unpaired t-tests were significant relative to untreated wild-type (WT) cells
(WT* p<0.03, ** p<0.0001; TNF  p<0.03,  p<0.0001; n=8 for all conditions).
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FIG. 13d Effect of ganglioside GD3 and GD1B, and of TNF, on gene expression of FRAG1. Experimental
conditions as in FIG. 13d. Differences by unpaired t-tests were significant relative to untreated wild-type (WT) cells
(WT* p<0.03, TNF p<0.0001,  p<0.007; n=8 for all conditions).
FIG. 13e. Effect of ganglioside GD3 and GD1B, and of TNF, on gene expression of IL3RA. Experimental
conditions as in Fig. 13e. Differences by unpaired t-tests were significant relative to untreated wild-type (WT) cells
(WT* P<0.05, **P<0.0002 *** p<0.0001; TNF p<0.0001,  p<0.002; n=8 for all conditions).
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FIG. 13f. Effect of ganglioside GD3 and GD1B, and of TNF, on gene expression of CCL2. Experimental
conditions as in Fig. 13f. Differences by unpaired t-tests were significant relative to untreated wild-type (WT) cells
(WT* p<0.003, ** p<0.0001; GD3 and GD1B  p<0.0001; n=8 for all conditions).

.
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DISCUSSION
MIP3A (Macrophage inflammatory protein 3, CCL20) - The function of this protein is to
serve as a chemotactic agent for lymphocytes.

It attracts lymphocytes and dendritic cells

eliciting its effects on the chemokine receptor CCR6. The expression of this protein can be
initiated by LPS or by inflammatory cytokines like TNF.

MIP3A normally activates

macrophages and recently has been described as having an impact on B-cells. It also plays an
important role in the development of experimental autoimmune encephalomyelitis (EAE), the
animal model of MS, during the sensitization phase (Krzysiek, Lefevre et al. 2000). Since
MIP3A acts as a significant leukocyte chemoattractant to antigenic sites and also as a ligand for
monocyte chemotactic protein-1 receptor (MCP-1), studies were performed on the blood samples
of multiple sclerosis patients before and after intravenous methylprednisolone treatment
(Michalowska-Wender, Losy et al. 2008). It showed a marked, but nonsignificant increase in the
levels MIP3A (Michalowska-Wender, Losy et al. 2008). MIP3A has also been associated with
TRAIL (TNF superfamily member 10) in allergic airway diseases such as asthma in which
symptoms manifest in an immediate response to a foreign pathogen. This results in immediate
cytokine/chemokine release for inflammatory pathways, targeting myeloid dendritic cells and Tcells expressing CCR6 to activated areas, which is similar to the relapse initiation period seen in
MS (Weckmann, Collison et al. 2007). Other research has provided evidence that Th-17 cells
play an important role in the migration of lymphocytes into the brain by a mechanism involving
a CCR6/MIP3A axis (Reboldi, Coisne et al. 2009). Th-17 cells are known to express CCR6 and
when knocked out, caused the inability of mice to develop EAE. Once WT Th-17 cells were
introduced into the mice with normal CCR6 expression, susceptibility to EAE was re-initiated in
the choroid plexus, where MIP3A was constitutively expressed in the epithelial cells. (Reboldi,
Coisne et al. 2009).
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The data in Fig. 13a. shows a significant increase in the expression of MIP3A between
both GD3 and GD1b treated primary brain cell cultures when compared to normal wild type and
TNF treated primary brain cell cultures. This may be due to the presence of glial cells in the
cultures, specifically microglia, increasing their transcription of MIP3A. This response to
ganglioside exposure may be due to their functional similarity to macrophages. Microglia only
proliferate during times of infection and remain in their quiescent state under normal conditions
suggesting that gangliosides may possibly play a role in their activation. .
FGF13 (Fibroblast growth factor 13) – The function of this protein and its family
members is to enhance cell survival, proliferation, embryonic development, tissue repair, cell
differentiation, and possibly play a role in cortical neuron differentiation. FGF proteins bind to
FGF receptors. FGF13 gene expression was drastically down regulated in the GD3 and GD1b
treated primary brain cultures when compared to normal wild type and TNF treated cultures.
This down regulation of FGF13 may be due to interference by ganglioside interaction with
FGF13 or its receptor. Some of the isoforms for FGF13 are FGF2 or FHF2. FGF2 has been
studied for its role in the recovery of multiple sclerosis,

where it has been shown to initiate

remyelination in animal models using MHV-A59, a murine hepatitis virus that causes
demyelinating spinal cord lesions which spontaneously remyelinate (Messersmith, Murtie et al.
2000). Oligodendrocyte cell lines were generated and increased amounts of FGFRs were seen in
the cell lines, specifically during times of remyelination, indicating that FGF2 may play a role in
the recovery and remyelination process of MS. Other studies have shown that gene therapy
using HSV-1 replication defective vectors containing the human FGF2 gene significantly
reversed the clinical symptoms of mice with chronic EAE even after 60 days post-treatment.
(Ruffini, Furlan et al. 2001).
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. Gangliosides GD3 and GD1b caused a significant down regulation of the expression of
FGF13 when compared to untreated, normal brain cell cultures and TNFtreated cultures (Fig.
13b). TNF treated cultures had a slight but nonsignificant increase on FGF13 expression when
compared to the normal, untreated cultures.

This provides evidence that gangliosides are

impairing the recovery and remyelination of these cultures or are maintaining the cultures in a
neurodegenerative state due to the significant reduction of FGF13 expression.
IL1R1 (Interleukin 1 receptor 1 aka CD121a) – This protein encodes a receptor for IL1a
and IL1b, and is an important mediator of immune and inflammatory responses. IL1R1 forms a
cytokine receptor complex with IL1R2, IL1RL2, and IL1RL1. This receptor has been shown to
interact with other proteins such as MYD88, which is an activator protein for all TLRs, which in
turn activate NF. In a recent study, MS patients with the HLA-DRB1*1501 genotype were
given one of the newer, immunotherapeutics, glatiramer acetate (Copaxone™), to determine its
effects on and associations with the expression of 27 potential genes having 61 single nucleotide
polymorphisms (SNPs).

IL1R1 was one of the genes that had a significant response to the

treatment along with 5 other genes, suggesting that these genes play a direct or indirect role in
the mode of action of glatiramer acetate (Grossman, Avidan et al. 2007). IL1R1 seems to play
an important role in recruiting CD3 T-cells to areas of neuronal injury. Studies in mice with
axotomised facial motoneurons showed high levels of CD3+ T-cell recruitment to sites of injury
causing neuronal death, but transgenic mice with IL1R1 knockout had a 54% reduction in
recruitment of CD3+ T-cells (Raivich, Bohatschek et al. 2003).
Overall, there was a significant increase in IL1R1 expression in GD3 treated cultures
when compared to normal, untreated cultures (Fig. 13c). But with GD1b treated cultures, there
was a significant increase in relative IL1R1 expression when compared to normal, untreated and
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TNF treated cultures. There was no difference in normal, untreated cultures when compared to
TNF treated cultures.
FRAG 1 (FGF receptor activating protein 1) – This protein acts as a stimulator for the
transforming activity and autophosphorylation of the FGF receptor. Not much is known about
FRAG1 and its role in MS or apoptosis however it has been hypothesized that FRAG1 plays
several roles as a surveillance protein during the S phase of the cell cycle: 1) monitoring
replicative stress,

2) regulation of genomic stability, and 3) determination of apoptosis (Ishii,

Inageta et al. 2005). When apoptosis occurs, it has been observed that the protein ATR down
regulates FRAG1, causing RAD9/BCL2 to co-complex and lead to the induction of the proapoptotic protein Bax (Ishii, Inageta et al. 2005). Frag1 has also been recently associated with
neuronal injury and death.

In previous microarray studies, neurons with either proximal or

distal axonal injury had increased expression of eight genes, including FRAG1, which was
confirmed by RT-PCR. (Yang, Xie et al. 2006).
In this study there was a significant decrease in FRAG1 expression in only the GD3
treated primary brain cell cultures when compared to all other conditions (Fig. 13d). TNF
treated cultures had a significant increase in FRAG1 expression when compared to normal,
untreated cultures.
IL3RA (Interleukin 3 receptor alpha aka CD123) – This is a cytokine receptor for
interleukin 3 that is a multipotent cytokine which promotes the differentiation of hemopoietic
progenitor cells into the myeloid (neutrophils, basophils, and eosinophils), erythroid (red blood
cells), and lymphoid cell (Natural killer cells, T-cells, and B-cells) lineages.

A popular

medication or immunotherapeutic for the treatment of MS is IFN-1 (trademarked as
Avonex™). The mode of action for Avonex™ is to manipulate the IL10/IL12 axis, causing a
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rise in IL10 therefore reducing or ablating the action of IL12, causing more of a TH2 antiinflammatory environment. Recent research has shown that this can be achieved by increasing
the amount of IL3RA (CD123). When IFN- was given to human blood monocytes derived
from myeloid dendritic cells, a dose dependent response was observed in the expression of
CD123, which is traditionally a classic indicator of plasmacytoid dendritic cells, and is coexpressed with blood dendritic cell antigen 4+ (BDCA4+). However these dendritic cells were
negative for another a traditional marker for plasmacytoid dendritic cells, BDCA2- (Huang,
Adikari et al. 2005). The significance of these findings was that the IFN- modulated dendritic
cells were found to only produce IL-10 and IL-6.

Furthermore, this IFN- administration

produced dendritic cells that predominantly secreted only IL-10 and were IL-12 deficient,
causing the TH2 anti-inflammatory environment (Huang, Adikari et al. 2005). Other studies
have seen similar outcomes in MS patients when it comes to IFN- treatment and circulating
blood levels of dendritic cells. It was confirmed that IFN- induced the expression of CD123 in
plasmacytoid dendritic cells and decreased the amount of circulating myeloid dendritic cells in
the blood of MS, IFN--treated patients. These results also suggest that the circulating dendritic
cells are being impaired in their maturation process allowing for a TH2 environment to prevail.
Fig. 13e. shows the relative gene expression of IL3RA in normal, untreated brain cell
cultures, and in those treated with GD3, GD1b, and TNFGD3 treatment caused a significant
reduction in IL3RA gene expression when compared to all other conditions. GD1 treated
cultures showed a significant decrease in IL3RA gene expression when compared to TNF
treated cultures only. IL3RA gene expression increased significantly when treated with TNF.
This provides evidence that ganglioside administration reduces the likely hood of having an antiinflammatory TH2 environment allowing for inflammatory processes to prevail.
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CCL2 (chemokine ligand 2 aka MCP-1) – This protein, when bound to CCR2 or CCR4,
functions to recruit monocytes, memory T-cells and dendritic cells to sites of infection or tissue
injury.

Recent studies have shown that chemokines, CCL2 being one of the four major

chemokines, play an important role in the migration of leukocytes to the CNS (Subileau, Rezaie
et al. 2009). Brain tissue samples from MS patients were taken and immunohistochemistry
staining was performed on the samples identifying four main chemokines in the endothelial cells
of the brain tissue samples (CCL2, CCL5, CXCL8, and CXCL10) (Subileau, Rezaie et al. 2009).
This group also showed that these human brain endothelial cells constitutively released CCL2,
but the release of CCL2 was increased in response to TNF and/or IFN in the hCEMC/D3 cell
line, a brain endothelial cell line (Subileau, Rezaie et al. 2009).
The chemokine receptor CXCR3 was up-regulated in cytokine stimulated cells while
CXCR3 was down-regulated in non-inflammatory, remitted MS lesions linking its expression to
times of relapse. There is evidence that glia-derived CCL2 plays an important role in the
induction of demyelinating diseases like MS. It has been demonstrated that irradiated chimeric
mice induced to have EAE had optimal disease states when glia cells produced CCL2, which in
turn attracted iNOS dendritic cells and TNF secreting macrophages to the brain initiating the
entry of lymphocytes and leukocytes into the CNS (Dogan, Elhofy et al. 2008).
There is also evidence that kinin b2 receptors play a role in the induction and severity of
EAE (Dos Santos, Roffe et al. 2008). This group, as well as the previous group, has shown that
CCL2 plays a role in leukocyte adhesion in the brain, but the mechanism involving kinin b2
receptor is unknown. Mice that lacked kinin b2 receptors were shown to have a reduction in the
chemokines CCL2 and CCL5 at day 14 in MOG induced EAE mice, lessening of disease
severity, and a significant reduction of adherent leukocytes to the brain (Dos Santos, Roffe et al.
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2008). This provides evidence that kinin b2 receptors play a role in the expression of CCL2 and
CCL5 as well as regulation of leukocyte recruitment in inflammatory processes in the CNS. The
natural receptor for CCL2 is CCR2. Recent advancements in research have suggested that CCR2
antagonists may be an effective therapeutic in inflammatory diseases (Xia and Sui 2009).
Fig. 13f shows the data for CCL2 gene expression between all groups. CCL2 gene
expression was significantly increased in all conditions when compared to WT; but the increased
expression associated with TNF surpassed that of the ganglioside treatments to a statistically
significant degree. This increase may be an effect of stimulation needed for glial activation and
proliferation seen in reactive gliosis, thus causing an increase in the expression of CCL2.
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Chapter V

DISCUSSION
Gangliosides in general, specifically GD3, have been implicated since the mid 1980’s in
the modulation of apoptosis in many neurodegenerative diseases. Seyfried (1985) was one of the
many investigators to compile and review this lone ganglioside and its role in apoptosis in
diseases

such

as

multiple

sclerosis,

Creutzfeld-Jakob

disease,

subacute

sclerosing

leukoencephalitis, Huntington's disease, Alzheimer's disease, and many more in association with
reactive gliosis. One of the hallmarks of reactive gliosis is the increase in GD3. Previous
research has shown that GD3 can be an intermediate of cellular apoptosis and has a direct
relationship with TNF

-Ruiz, Colell et al. 2002). Most of the earlier studies focus on the

interaction of ganglioside GD3 with the mitochondria, but do not thoroughly address the cellular
interactions or responses that cause the cell to undergo apoptosis and the differential expression
of additional potential targets involved in the GD3-mediated apoptotic pathway (Kristal and
Brown 1999; Garcia-Ruiz, Colell et al. 2000; Garcia-Ruiz, Colell et al. 2002; Malisan and Testi
2002; Morales, Colell et al. 2004; Jou, Lee et al. 2006). It has been hypothesized that GD3mitochondrial associations can lead to the inhibition of NF expression in neurons and
hepatocytes, thus stopping the activation of the survival pathway and activation of apoptosis
(Morales, Colell et al. 2004). Many other genes in multiple brain cell types may be involved in
this pathway with multiple effects on gene expression and in conjunction with other cytokine
stimuli. Yet, little is known about the biosynthetic modifications made to the ceramide or
carbohydrate moieties of the gangliosides once the initiation of apoptosis has begun. Even less
information is known on the cellular pathways involved in this unique form of cell death that is
initiated in the CNS without the initial involvement of the peripheral immune system. This
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research sought to elaborate on the cellular cascade and possible cellular pathways involved in
cell death initiated by gangliosides GD3 and/or GD1b, and their effects on gene expression in
multiple brain cell types.
Viability
F11-A Neuroblastoma Family of Cell Lines
My first experimental approaches were designed to analyze the viability of cells that lack
the ability to synthesize any complex gangliosides past GM3. This led to viability experiments
using a family of F11-A neuroblastoma cell lines, in which one cell line does not express STII or
GNT (F11-A), one cell line expresses only STII (STII), and one cell line expresses only GNT
(GNT) (Fig. 2). If GD3/GD1b do in fact work together with TNF to cause cell death, this
method should isolate specific ganglioside patterns, or a particular series of gangliosides, which
lead to an increase in cell death in conjunction with varied concentrations of TNF.
Experiments with these immortalized cell lines did provide some justification to this
hypothesis. Fig 2 shows the HPTLC of the F11-A, STII and GNT cell lines. Each cell line had a
distinct and specific ganglioside pattern. The only cell line able to synthesize GD3 was the STII
transfected cell line, while GNT cells had more GD1b and two GD1a isoforms while the F11-A
cell line only had GM3. Varied amounts of TNF (0-1.0M) were given to the three cell lines
and were analyzed for viability by MTS after 24h. Fig. 3 shows the results of the MTS assay
(n=6). F11-A cells were unphased by the application of TNF at any concentration while STII
cells showed a significant and increasing reduction in viability as TNF concentrations
increased. GNT cells had a noted but insignificant decease in viability at the highest TNF
concentration (p<0.08). This data supports the theory that gangliosides, specifically GD3, cause
a reduction in viability consistent with cell death.
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GNT Gene Expression
Bieberich et. al.(2002) have shown that ganglioside biosynthesis is coordinated in a
complex fashion, meaning that glycosyltransferases must complex together and, in essence,
activate one another for proper ganglioside biosynthesis. This is important because GD3 is not
normally seen in the developed brain. Ganglioside biosynthesis may be up-regulated in order to
increase the endogenous pools of gangliosides, so that more complex gangliosides like GD1b can
then be modified by glycosidase cleavage to produce the simpler gangliosides like GD3. Fig. 8
shows the comparison of wild type cells with TNF treated primary brain cell cultures. There
was a significant increase in GNT expression which provides evidence suggesting that
ganglioside biosynthesis is up-regulated when cell cultures are exposed to a pro-inflammatory
stimulus like TNF.
Primary Brain Cell Viability
My next experiment was designed to test the viability of primary brain cell cultures based
on the previous findings that gangliosides, specifically GD3, in conjunction with TNF, can
cause cell death in neuroblastoma cell lines. This allows for a more physiologically relevant
system to test the hypothesis that gangliosides and TNF work together to initiate cell death.
Besides ganglioside GD3, previous studies have failed to fully investigate whether ganglioside
GD1b can initiate neuronal apoptosis, since it is more highly expressed in normal adult brains
than GD3 and can be modified by catalytic enzymes, like glycosidases, to become GD3 (Malisan
and Testi 2002). GD3 plays a very important role in gestational development of the brain itself
and the overall nervous system (Irwin, Michael et al. 1980), but is rarely seen in the adult brain
unless a disease state like MS has been activated and reactive gliosis occurs, causing a shift in
the readily available pool of gangliosides (Jou, Lee et al. 2006). This phenomenon may be
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attributed to the role that GD3 plays during development; possibly for clearance of undeveloped
or unnecessary cells formed during gestation.

Experiments have been conducted by many

groups to elucidate the mitochondrial processes that play a combined role with GD3 in neuronal
apoptosis. A novel human sialidase enzyme, Neu4L, was isolated by biochemical fractionation
and contained two isoforms, one with an N-terminal sequence and another that lack the sequence
(Yamaguchi, Hata et al. 2005). The two proteins were labeled with a fluorescent tag and only
the protein containing the N-terminal sequence was located in the mitochondria while the other
isoform was located in intracellular membranes. Also, amino acid mutations of the N-terminal
isoform, within the N-terminal region, showed the lack of mitochondrial localization, suggesting
that this (1) N-terminal sequence is a tag sequence specific for trafficking to the mitochondria
and (2) sialidase may play a role in apoptosis using GD3 specifically as a substrate (Yamaguchi,
Hata et al. 2005). Neu4L has also been shown to be specifically expressed in the brain, have a
dramatically decreased level of expression prior to the induction apoptosis, and to increase its
expression while GD3 increases its localization in the mitochondria (Hasegawa, Sugeno et al.
2007). This, in conjunction with numerous other research on the subject, led me to perform
MTS viability assays on primary brain cell cultures to support the view that gangliosides can
mediate cell death, and to establish a baseline for future experiments involving gangliosides and
TNF.
The next objective of this research was to first establish a physiologically relevant cell
culture system which incorporated primary, mixed brain cells, and then to treat them with mixed
brain gangliosides plus a pro-inflammatory cytokine, TNF, to establish a possible causal link
integrating the nervous system and its immune function. The purpose for using mixed brain
gangliosides is the fact that these gangliosides are normally expressed in the developed
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mammalian brain.

If there was an independent or interactive decrease in primary brain cell

viability using mixed brain gangliosides with/or without a pro-inflammatory cytokine, this
should support the theory that gangliosides can affect brain cell viability whether it be by direct
cellular interactions or indirectly through enzymatic modification.

Any form of these

interactions, directly or indirectly, should lead to an alteration of the brain cell’s gene expression.
Fig. 5 shows that there is a strong possibility that gangliosides can cause cell death independently
of TNF. TNF only seemed to have a marginal effect in conjunction with co-administered
gangliosides, and, when administered by itself, had the opposite effect of causing an increase in
the viability of the primary brain cell cultures. This could be due to the increased amount of glial
cells to neurons in culture. The brain is composed of approximately 90% of brain tissue glial
cells (Nair, Frederick et al. 2008), which is why co-cultures of cortex and hippocampus were
used in hopes of increasing the neuronal population and elucidating the interactions of these two
cellular subtypes (cortex with hippocampus). It has been stated that LPS, inactivated bacteria,
and TNF can cause an increase in the production of GD3 in microglia without reducing their
viability (Simon, Malisan et al. 2002), therefore possibly causing the proliferation and migration
of microglia and astrocytes to sites of injury or infection and initiating the beginning stages of
cell death. This is possibly why an initial increase in viability in TNF treated cultures was
noticed. This phenomenon can be seen in the lesions of patients with neurodegenerative diseases
such as multiple sclerosis, since the areas of injury are essentially filled in by glial cells. This
functions to prevent further neuronal death in the brain, but at the same time prevents the
regeneration of neurons and oligodendrocytes leading to permanent dysfunction. Simon (2002)
has also shown that the attack by the self immune system can be targeted towards the
oligodendrocytes, which could cause a secondary, downstream apoptotic cascade to occur in the
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neurons themselves. One other interesting note is that peripheral lymphocytic cells produce GD3
during apoptosis, suggesting one causal link in the process of apoptosis (Simon, Malisan et al.
2002).
Since I had demonstrated that exogenously applied mixed brain gangliosides cause a
definite reduction in primary mixed brain cell viability regardless of the presence of exogenously
applied TNF (Fig. 5, n=3), I then sought to support the theory that gangliosides GD3 and/or
GD1b may be the responsible glycolipid/s in the mediation of this form of cellular death. These
two gangliosides are very closely related in the ganglioside biosynthetic pathway, in that the only
difference in their structures is the addition of the GalNac and terminal galactose to a GD3
precursor, while both maintain the two sialic acid moieties on the internal galactose carbohydrate
(refer to Fig. 1). The amount and relative positioning of sialic acid on gangliosides, as well as
other glycans, is of great importance, since they have been known to act as antigen binding sites
for pathogens and can affect the overall cellular physiology during autoimmune dysfunction
(Schauer 2009). Since GD3 is not normally expressed in differentiated, developed neurons, it is
possible that ganglioside GD1b may be modified within the microglia by glycosidase cleavage
into GD3, and may be secreted, causing a build-up of GD3 within oligodendrocytes and neurons.
So additional experiments were performed on these primary brain cell cultures using varied
amounts of GD3 in conjunction with varied amounts of TNF to further investigate if the
smaller, more primitive GD3 could be essential in the modulation of cell death.

In the

concentration range for GD3 of 1.6nM to 160M, in the presence of 200nM TNF, the viability
of the primary brain cell cultures (compared to wild type) were consistently reduced, regardless
of concentration (Fig. 6). Other experiments using a constant 160M GD3 concentration with
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varied amounts of TNF (2 pM to 200 nM) showed the exact same results (Fig. 6). This led me
to conduct more relevant time course studies involving this phenomenon.
Fig. 7 shows the time course study involving the combination of GD3 with TNF Fig.
7a shows that after 24h, the combination of GD3+TNF caused a significant reduction in
primary brain cell viability (n=3). Fig. 7b shows that neuronal viability was reduced after a 48h
incubation period when GD3, TNF, and the combination of the two were administered (n=3).
Although, exposure to GD3 alone was the only condition to continue to have a marked decrease
viability after 72h when compared to the combination of GD3+TNF (Fig. 7c, n=3), this
suggested that GD3 has a potent effect on viability with and without TNF at this concentration
(160M), possibly on oligodendrocytes and neurons. This obscure TNF phenomenon could be
due to microglia/astrocytes needing a pro-inflammatory stimulus signal to cause their activation,
not death since they are the resident immune cells in the CNS, which in turn would lead to an
increase in their endogenous amounts of GD3 for secretion to neuronal or oligodendrocyte
populations, thus causing cell death for the neuronal population. This phenomenon can be
observed in MS lesions where increases in inflammation and neuronal death are eventually
reduced, only to be followed by rapid astrocyte proliferation to fill in damaged areas thus causing
scarring in the brain. Although GD1b didn’t cause an initial decrease in viability over the 24h
incubation period in conjunction with TNF, it still doesn’t exclude it from possibly modulating
cellular apoptosis independently due to its homologous biochemical structure when compared to
GD3, which might be the key to the initiation or the mediation of cellular death, and its noted
reduction in viability with the F11-A-GNT MTS assay (Fig. 3). However, more mechanistic
approaches are needed to determine the pathway involved in ganglioside-mediated cell death.
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In order to elucidate a hypothetical pathway for ganglioside-mediated cell death, a
microarray analysis of gene expression in mixed brain cell cultures treated independently with
GD3, GD1b, and TNF was carried out. This was based on the assumption that it is important to
look at the individual effects first due to the fact the gangliosides by themselves can cause a
decrease in cell viability, and determine a baseline function of the individual components when it
comes down to gene expression. Later experiments should be conducted to look at the changes
in gene expression when these components are added together.
Gene Expression
Figure 10 shows the preliminary results of the ORN-11 microarray data for inflammatory
cytokines and receptors on wild type, GD3, and GD1b treated neurons.

Overall, TGFB2,

TGFB3, and TIEG, which are involved in the inflammatory pathways that cause apoptosis, were
down regulated in the ganglioside-treated primary brain cultures. However FGF1, FGF2 and
FGFR3, which are involved in cell proliferation, were down-regulated as well. This suggested
that gangliosides may mediate apoptosis in a more complex manner than originally stated, and
could lead to the discovery of novel cellular death pathways possibly involving more than one
brain cell type. But this was a sample size of 1, so experiments were repeated with 2 arrays for
all conditions, for a more reliable determination of target genes (discussed later).
Figure 11 shows the ORN-22 microarray data for chemokines and their receptors. The
data shows that ganglioside GD1b causes an up-regulation of multiple targets: (1) MYD 88, the
universal adaptor protein used by Toll Like Receptors to activate NF 1; ( 2) NF 1, which is
involved in autoimmune diseases by using toll-like receptors (TLRs) and TNF receptors; (3)
RDC1, a chemokine receptor used in immune system targeting and functionality; (4) SCYE 1, a
cytokine that induces apoptosis by TNF; and (5) SDF 2, all of which are involved in apoptosis
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through TLR/TNF - mediated pathways. These targets suggested that (1) the immune system
could interact with cells like microglia and astrocytes, (2) could be involved in the inflammatory
death of these primary brain cell cultures and (3) that gangliosides play a role in these concerted,
initial events leading to cell death.
These initial findings suggested the need to concentrate on the ORN-11 microarray data
specific to inflammatory targets, so I chose to repeat this experiment using WT, GD3, GD1b, and
TNF treated cells with an n=2 for each condition (8 total arrays). Fig. 12 shows the results of
the microarrays, quantified as the relative percent changes seen between potential target genes in
Fig. 13a-e. The relative hybridization of the probes to the arrays were normalized by adjusting
the relative intensity of the housekeeping genes on each array to one another using the Quantity
One ™ software program and collecting numerical data points for each gene. Genes were then
compared by relative percent change.
On the basis of the microarray results, 13 genes were selected for further study by qPCR.
Out of the 13 genes whose expression was analyzed, only the 6 listed in Chapter 4 and 1 of the
ganglioside biosynthetic enzyme genes (MIP3A, FGF13, IL1R1, FRAG1, IL3RA, CCL2, and
GNT) showed a significant overall change in their gene expression (Fig. 8 &13a-13f).
In order to propose a pathway involving gangliosides and/or TNF in cell death
cascades, the initial events involved in this cellular orchestration have to first be defined. These
initial events must lead to an increase in the pro-inflammatory cytokine TNF and the release of
gangliosides by injured brain cells. TNF has been noted to cause the activation and the
increase of GD3 in microglial cells and cause an overall increase in astrocytic populations. Once
these factors have been released, all cell types involved in the cultures began to change their
overall gene expression when compared to wild type. Most of the changes were seen in the
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ganglioside-treated cells. All gene data and their known functions were discussed in Chapter IV.
A further discussion on the possible functions and interactions of these genes within a proposed
pathway leading to cell death is discussed below, incorporating additional targets and genes
found in the literature.

Proposal for a Hypothetical Pathway Leading to Cell Death Involving Gangliosides/TNF
TNFGanglioside Functions in Cell Death in the CNS
TNF

mportant role in

neurodegeneration and cell death. GD3 and TNF interactions have been studied in various cell
types with the emphasis that these interactions disrupt the mitochondrial membrane causing
caspase activation (Garcia-Ruiz, Colell et al. 2000; Garcia-Ruiz, Colell et al. 2002). Microglia
treated with gangliosides have been known to increase their expression of TNF (Min, Pyo et al.
2004) and increase their expression of COX-2 and NO (Pyo, Joe et al. 1999) implicating
gangliosides as a mediator of microglial activation. Activated microglia have also been known
to secrete GD3 which they otherwise do not synthesize under non-pathological circumstances.
Simon (2002) has shown that oligodendrocytes are especially susceptible to apoptosis induced by
exogenous GD3. There is also evidence that gangliosides can disrupt the myelination of neurons
by oligodendrocytes by interfering with myelin-associated glycoprotein (MAG4) (siglec4)
binding to gangliosides with the terminal sequence of NeuAca2–3Galb1–3GalNAc, which
include GD1a and GT1b (Lopez and Schnaar 2009). As of late, astrocytes have been found to
modulate several processes in immune-mediated pathologies.

Astrocytes increase their

expression of TNF once they undergo activation, and may be able to mediate TH2/TH1 cellular
environments (Nair, Frederick et al. 2008). It has also been stated that when astrocytes release
TNF, there is an increased permeability at the blood-brain barrier allowing for easier entry of
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lymphocytes into the CNS. These are just a few examples of how gangliosides, TNF, and the
combination of the two can play a role in pathologies within the CNS.
Microglia
Once microglia are activated by GD3/TNF, they have to increase their intracellular
amounts of GD3, which can possibly be attributed to the significant increase in GNT that we
observed in our experiments (Fig 8). Once the microglia have built up their supply of GD3,
there is a noticeable and significant decrease in the gene IL3RA Fig. 13e). This reduction allows
for the modulation of a TH1 pro-inflammatory environment because the normal function of this
gene is to increase IL10 which normally produces an anti-inflammatory environment creating
TH2 type lymphocytes. This leads to an increase in IL-12 and thus increases the amount of TH1
lymphocytes causing inflammation. A reduction in IL-10 can also result in an increase in nitric
oxide (NO) build up within the cell which causes an increase in NF and iNOS expression.
More evidence is starting to mount for genes like CCL2 in diseases like multiple
sclerosis. This gene could easily be attributed to microglial and astrocyte activation since both
types of glial cells express it and can have the same pathways activated in relation to CCL2, but
this section is theoretically related to microglial function. Samples of postmortem brain tissue
lesions from human patients with multiple sclerosis have shown a high increase in CCR2, the
receptor for CCL2, which can be found on foamy macrophages and activated microglia
(Simpson, Rezaie et al. 2000).Kim (2002) has also shown that gangliosides can act to activate
microglial cells, and possibly astrocytes, in the brain by means of the Jak/Stat pathway, causing
an increase in the gene expression of CCL2, along with intracellular adhesion molecule (ICAM)
and inducible nitric oxide synthase (iNOS). It is possible that the increase in CCL2 is coming
from both glial cell types when exposed to gangliosides but it is also probable that both glial
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types dramatically up-regulate CCL2 in the presence of TNF
in CCL2 by microglia may be a function of toll like receptors complexing with IL1R1, forming a
toll/interleukin receptor (TIR) domain which causes an increase in CCL2. This is discussed
further below.
The gene data presented here also showed a significant increase in IL1R1 in the
ganglioside-treated cultures.

IL1R1 normally binds to IL1, which acts as an endogenous

pyrogen, and is critical in the function of the immune system. Raivich (2003) has performed
studies using the immunotherapy drug glatiramer acetate (Copaxone™) for the treatment of
multiple sclerosis. This drug has been shown to significantly reduce IL1R1 in human trials, thus
slowing the progression of MS. Raivich (2003) has shown that IL1R1, in conjunction with
TNFR2 may possibly play an initial and critical role in the recruitment of lymphocytes to the
CNS in a mouse motoneuron model, while IL1R1 also possesses the unique ability to complex
with TLRs (Muzio, Polentarutti et al. 2000; O'Neill 2000; O'Neill 2002; Nyati, Prasad et al.
2009), which are known to bind to LPS, causing the activation of myeloid differentiation primary
response gene (88) (MYD88) and eventually NF
activation. Other evidence has suggested that gangliosides themselves can activate TLRs (Jou,
Lee et al. 2006; Yoon, Jeon et al. 2008), which may be the reason for the increase of IL1R1 in
order to increase the amounts of TIR domains. Fig. 13c shows that only GD3 and GD1b cause
an up-regulation of IL1R1. Since microglia come from the same cell lineage as macrophages, it
would be highly likely that microglia would up-regulate the expression of IL1R1 in order to
recruit or activate other macrophages, astrocytes, or other infiltrating lymphocytes to the CNS or
increase its ability to capture gangliosides using TLRs, thus initiating the appropriate cellular
pathways.
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One other interesting side note is the expression of FRAG1. FRAG1 is known to activate
FGF receptors and modulate mitogenic functions, but Ishii (2005) has shown that downregulation of FRAG1 leads to the release of cell cycle checkpoint control protein RAD9 (RAD9)
and allows for its association with BCL2. This then allows for the induction of the pro-apoptotic
protein BAX and eventually leads to cell death. Fig. 13d shows that GD3 caused a significant
decrease, while TNF caused a significant increase in FRAG1 expression. This is probably due
to the different responses of the various cell types within our primary mixed brain cell cultures.
Since glial cells seem to need TNF for activation and proliferation, it makes sense that the glial
cells would up-regulate their expression of FRAG1 for increased survivability and activity.
Conversely, GD3 would cause the down-regulation of FRAG1 in neurons by acting as an
antagonist on FGF receptors.
All of this evidence together suggests that TNF and ganglioside interactions cause an
up-regulation cell death cascades through (1) an increase in the expression of GNT, leading to
elevated levels of gangliosides like GD1b, which maybe modified to GD3, which induces death
in neurons and oligodendrocyte upon its release from microglia. ( 2) The up-regulation of IL1R1
would increase the microglial ability to recruit or activate other immune cell types by increasing
TIR domains for ganglioside-mediated activation, leading to increased CCL2 expression which
would cause microglial/astrocyte survival and proliferation by activation of the TIR-Myd88NF pathway, indirectly increasing FRAG1 expression due to the glial cells ability to become
activated by TNF
within the CNS, and (4) an increase in CCL2 targeted to the blood brain barrier for peripheral
immune cell recruitment/migration.
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Astrocytes
Once gangliosides and TNF have activated astrocytes, there is a noticeable and
significant increase in the gene expression of MIP3A and CCL2. At the same time, gangliosides
that have been released by activated microglia or by injured brain cells, are influencing pathways
related to protein receptors at the cell surface. Many gangliosides have been known to influence
the phosphorylation/activation of Jak 1 and 2 receptors (probably similar to the process in
microglia) causing Stats to translocate into the nucleus and activate  interferon activation site
(GAS)/interferon stimulated response element (ISRE) promoter sites, leading to an increase in
the transcription of CCL2, iNOS, and ICAM. It has recently been observed that glial-derived
CCL2 plays an important role in the recruiting and attraction of dendritic cells that secrete iNOS
and TNF

(DoganElhofyet.al Xia (2009) has

compiled a review on the use of the CCR2 antagonists, which inhibit the binding of CCL2, and
their possible use as a therapeutic agent due to their successful reduction of inflammation and
monocyte chemotaxis.



MIP3A is of great significance in the breakdown of the blood brain barrier and in the
modulation of infiltrating lymphocytes into the central nervous system. The blood brain barrier
is composed mainly of astrocytes, which secrete MIP3A and modulate the increased migration of
immature myeloid dendritic cells to the inflamed central nervous system (Ambrosini, Remoli et
al. 2005). Ambrosini (2005) has also shown that CCL2 as well as MIP3A is increased in reactive
astrocytes. This allows for circulating lymphocytes to tether to selectins and integrins, and use
MIP3A and CCL2 as a molecular trail to enter the central nervous system. There is also
evidence that astrocytes release pro-inflammatory cytokines like IL-6 and TNFwhich cause an
increased permeability at the blood brain barrier by affecting the endothelial cells and tight
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junctions found there (Nair, Frederick et al. 2008). By using either the former or latter, or a
combination of both mechanisms, it is clear that astrocytes mediate the influx of peripheral
immune cells into the CNS.
Reboldi (2009) has shown that mice lacking CCR6, the natural receptor for MIP3A, are
highly resistant to the induction of EAE. This is due to the lack of the ability to recruit TH-17
helper T cells, which is one of the defining characteristic of these helper T cells is the presence
of CCR6 (Reboldi, Coisne et al. 2009). Activated astrocytes that produce MIP3A can affect
microglia and cause them to produce IL-1 and iNOS (Terao, Ohta et al. 2009). Fig. 13a shows
that both GD3 and GD1b cause a significant increase in MIP3A expression. This indicates the
possibility that gangliosides themselves can influence the production of MIP3A, which could in
turn then lead to an increase in TNF
#46}. Fig. 13f shows that TNF caused a dramatic increase in CCL2, which could be a function
of either microglia, astrocytes, or a combination of the two.
Another gene that was shown to be significantly decreased was FGF13. FGF13 acts as a
growth factor for the support and survival of neurons. Although FGF13 has been described as
similar to FGF2, FGF13 has recently been associated with proper axonal propagation and has
even been linked to specific pathologies such as Borjeson-Forssman-Lehmann syndrome (BFLS)
which is an X-linked form of mental retardation (Gecz, Baker et al. 1999). FGF13 associates
with Na(v)1.6, a sodium channel found at the nodes of Ranvier on neuronal axons, and is
important in the fast inactivation of these sodium channels in neuronal cells(Rush, Wittmack et
al. 2006; Goetz, Dover et al. 2009). So it is logical that astrocytes act to support neurons in their
growth, development, functionality, and differentiation. Fig. 13b indicates that only GD3 and
GD1b cause a significant decrease in the expression of FGF13, whereas TNF had no effect on
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its gene expression. This means that astrocytes are playing a dual role in this gangliosidemediated form of cell death by decreasing their secretion of growth factors like FGF13 while
simultaneously increasing their amounts of MIP3A and CCL2 for the recruitment and invasion
of peripheral lymphocytes into the central nervous system to aid in the immune response.
What all of this information suggests is that activated astrocytes can play a dual role in
apoptotic events in the CNS.

Astrocytes can be activated by gangliosides released from

microglia or injured brain cells, causing an increase expression of the pro-inflammatory
cytokines CCL2, MIP3A, and TNF. These factors mediate lymphocyte entry and inflammation
in the CNS, and activate microglia to produce IL-1 and iNOS. On the other hand, activated
astroglia stop producing factors like FGF13 that enhance proliferation, differentiation, and
functionality of neurons. So it seems that astrocytes play a mediating role in inflammation by
activating glial cells, attracting peripheral lymphocytes, and by halting the proliferation and
functionality of neurons.
Neurons and Oligodendrocytes
At this point, the neuronal population is being bombarded by GD3 and all of the other
factors released by the microglia or astrocytes, and are not receiving any growth factor support
from these cells. It has long been known that gangliosides bind to growth factor receptors such
as FGF1 and FGF2, and antagonize any stimuli related to proliferation in neurons. I found a
significant reduction in the gene expression of FRAG1, which aids in the phosphorylation and
eventual activation of FGF receptors, in cell cultures treated with GD3. Ishii (2005) has shown
that a subsequent loss of FRAG1 phosphorylation of FGF receptors can lead to an increase in the
pro-apoptotic protein BAX. In my experiments, GD3 treated cells showed a significant decrease
in FRAG1 expression (Fig. 13d), suggesting that the neuronal population is being killed off
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while TNF treated cultures are causing an increase in FRAG1 expression and the consequent
thriving of the glial population.
IL3RA mediates the cellular environment by increasing the TH2 population, allowing for
a more anti-inflammatory targeted immune system. It would only make sense that neurons
would up-regulate their expression of IL3RA during normal physiological conditions while
reactive glial cells would down regulate their expression of IL3RA. Huang (2005) has shown
that approved medications for multiple sclerosis like Interferon-beta (IFN-beta 1 alpha),
Avonex™, can act on dendritic cells by suppressing IL12 expression and increasing IL10
expression. IFN-beta has been shown (Lopez, Comabella et al. 2006) to increase the expression
of IL3RA in peripheral dendritic cells (PDC) and decreased the number of circulating myeloid
dendritic cells (MDC) Fig. 16e shows that cultures treated with TNF increased their expression
of IL3RA, which may be a mechanism that neurons use to protect against inflammatory stimuli.
Cultures treated with GD3 or GD1b showed reductions in IL3RA expression, which is probably
due to the glial populations converting a TH2 environment to a TH1 environment.
Oligodendrocytes can be grouped with neurons due to their intimate support of neuronal
function and viability. The so-called “glue” that holds the myelin sheath to the axon of the
neuron involves a very special interaction between MAG-4 (siglec 4, a sialic acid binding
galectin) and gangliosides, specifically those that contain the specific terminal sequence of
NeuAca2–3Galb1–3GalNAc, including GD1a and GT1b (Lopez and Schnaar 2009). If the
secreted GD3 was to bind and enter into the membrane of the myelin sheath, this could cause the
myelin sheath to slough off, causing a neurodegenerative state and essentially killing off the
neuron. Lopez (2009) has stated that mice lacking GM3 synthase, STII, and GNT have all
displayed axonal degeneration and dysmyelination similar to that found in MAG-null mice.
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Besides its role in lymphocyte recruitment, CCL2, which is released by microglia or
astroctyes and governed by the Jak/Stat pathway, as well as TNF secretion, and/or TIR domain
activation can cause direct activation of caspase activity through cytochrome c release. This
could lead to an increase in the transcription of BAX, causing cell death (Kim, Park et al. 2002)
which can lead to the decreased viability of neurons and oligodendrocytes.
All of this information taken together suggests that neurons and oligodendrocytes are
being injured or killed by the influx of gangliosides, which can induce cell death by (1) the
antagonistic effect gangliosides have on FGF receptors, (2) the lack of FGF13 secretion to help
support neuronal viability and function, (3) the loss of FRAG-1 phosphorylation of FGF
receptors leading to BAX induction, (4) ganglioside uptake by oligodendrocytes, causing MAG4-ganglioside interactions to fail, resulting in demyelination, with (5) IL3RA increasing as a
result to prevent inflammation and hopefully cell death.
Below is a compilation of pathways showing how gangliosides and TNF might interact
to mediate cell death (Fig. 14). This is a summary of the gene expression data obtained from my
experiments, combined with what is known in the literature about the subject. Most of the model
is based on information from the literature about the functionality of specific brain cells.
However, my research on gene expression, as reported here, adds a new level of insight into
pathways likely to be involved in the apoptosis of brain cells.
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Fig. 14. Proposed Hypothetical Pathway Involving Ganglioside/TNF Mediated Brain Cell Death. This
diagram shows the possible effects of the genes found by micro array analysis (*) that were quantified by qPCR,
along with some of the other known genes/targets that have been found in the literature to play a role in
ganglioside/TNF mediated cell death.
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CONCLUSION
Gangliosides have been studied for many years and still have a relatively unknown
normal function. They are best known for their roles in disease and pathology but are still highly
debated as legitimate players in cell death. I believe that my research has shed a little more light
on the legitimacy of gangliosides as efficient cell death effectors.
I demonstrated that gangliosides, specifically GD3, can cause significant reductions in
primary brain cell viability with TNF exposure for up to 48 hours. I have also shown that
gangliosides can induce the expression of pro-inflammatory cytokines involved in many
neurological pathologies. It may also be possible that exogenous gangliosides can change the
overall global ganglioside pattern, in culture, resulting in changes in gene expression leading to
cell death.
This experiment was designed to elucidate some of the genes being expressed during the
initiation of cell death within the central nervous system caused by gangliosides and TNF.
Much of the literature emphasizes the combination of the two, but my approach was to first
determine the individual effects of each component when studying a pathway as misunderstood
and complex as this one. Future gene expression experiments should be carried out by treating
primary brain cell cultures with the combination of gangliosides and TNF in order to determine
if their interaction induces any other genes to play a role in this pathway.

This information

should lead to pathologically direct pathways involving autoimmune disease within the CNS,
uncover processes involved in neuronal degeneration, and uncover potentially new therapeutic
targets for diseases such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis.
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